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1  Summary 
1.1  Abstract 
Induction of an innate immune response requires recognition of pathogen associated 
molecular patterns (PAMPs) by pattern recognition receptors (PRRs). However, pathogens 
like the Hepatitis C virus (HCV) have evolved mechanisms to evade innate immune responses 
in infected host cells. HCV specifically infects hepatocytes, thus specialized immune cells are 
not affected by the immune modulatory mechanisms exerted by HCV. Indeed, it was observed 
that plasmacytoid dendritic cells (pDCs) recognize HCV infected cells and respond with IFNα 
secretion. In this study the response of innate immune cells against HCV was further analyzed 
in a co-culture of HCV subgenomic replicon (SGR) cells and peripheral blood mononuclear 
cells (PBMCs). 
It was confirmed that IFNα is produced by pDCs in this co-culture and it was shown that the 
secreted IFNα inhibits viral replication. Subsequently, it was demonstrated that pDC activation 
is triggered by viral RNA and that recognition of viral RNA in pDCs is dependent on TLR7. The 
transfer of viral RNA from infected cells into pDCs required cell-cell contacts. Following the 
characterization of the pDC response, a Luminex assay was performed to detect further 
cytokines and chemokines secreted by PBMCs in response to HCV SGR cells. As secretion of 
IFNγ was detected, NK cells were assumed to be activated. NK cell depletion from PBMCs 
resulted in loss of IFNγ, proving that NK cells are the source of IFNγ. Moreover, it was 
observed that also monocytes play a role in the anti-viral response. Flow cytometry and 
ImageStream analysis revealed an uptake of particles from HCV SGR cells by monocytes. 
The particles were found to be apoptotic vesicles, as PBMCs induced apoptosis in HCV SGR 
cells via tumor necrosis factor-related apoptosis inducing ligand (TRAIL) expression on NK 
cells. However, interactions between pDCs, NK cells and monocytes were required for efficient 
clearance of HCV SGR cells, as purified immune cells alone did not kill HCV SGR cells. 
Although expression of TRAIL receptors was comparable in HCV SGR cells and Huh-7 control 
cells, HCV activated PBMCs specifically targeted HCV SGR cells without killing Huh-7 control 
cells. The specific kill of HCV SGR cells was finally explained by the observation that HCV 
SGR cells are sensitive towards TRAIL induced apoptosis.  
In summary it was shown that next to pDCs also NK cells and monocytes contribute to the 
response against HCV. Most importantly, the results underline the necessity of the interplay 
and mutual activation of different innate immune cells to initiate an efficient, rapid and specific 
response against HCV infected cells.  
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1.2  Zusammenfassung 
Eine Antwort des angeborenen Immunsystems wird durch die Erkennung von Pathogen-
assoziierten molekularen Mustern durch Mustererkennungsrezeptoren ausgelöst. Pathogene wie 
das Hepatitis C Virus (HCV) verfügen jedoch über Mechanismen, die die angeborene 
Immunantwort in infizierten Zellen zu unterdrücken. HCV infiziert spezifisch Leberzellen, wodurch 
spezialisierte Immunzellen nicht von den immun-modulatorischen Mechanismen des Virus 
betroffen sind. Tatsächlich wurde beobachtet, dass plasmazytoide Dendritische Zellen (pDC) HCV 
infizierte Zellen erkennen und IFNα sekretieren. In dieser Arbeit wurde die Antwort des 
angeborenen Immunsytems gegen das HCV näher untersucht, indem HCV subgenomische 
Replikonzellen (HCV SGR Zellen) mit Immunzellen aus dem Blut (PBMCs) ko-kultiviert wurden. 
Es wurde bestätigt, dass in der Ko-Kultur von PBMCs mit HCV SGR Zellen IFNα von pDCs 
produziert wird und dass IFNα die virale Replikation inhibiert. Anschließend wurde gezeigt, dass 
die pDC Aktivierung durch virale RNA ausgelöst wird und dass diese durch TLR7 in pDCs erkannt 
wird. Der Transfer viraler RNA von infizierten Hepatozyten in pDCs erforderte direkten Zell-Zell 
Kontakt. Nachdem die pDC Antwort charakterisiert wurde, wurde eine Luminex Messung 
durchgeführt, um weitere Zytokine und Chemokine, die in dieser Ko-Kultur von PBMCs sekretiert 
werden, zu entschlüsseln. Die Detektion von IFNγ lieferte einen Hinweis, dass NK Zellen an der 
Immunantwort gegen HCV beteiligt sind. Dies wurde bestätigt durch Depletion von NK Zellen aus 
PBMCs: unter diesen Bedingungen konnte kein IFNγ mehr gemessen werden. Darüber hinaus 
wurde entdeckt, dass auch Monozyten in der anti-viralen Immunantwort eine Rolle spielen. 
Durchflusszytometrie und ImageStream Analysen zeigten eine Aufnahme von Partikeln von HCV 
SGR Zellen durch Monozyten. Diese Partikel wurden als apoptotische Vesikel identifiziert, da 
PBMCs durch Expression von TRAIL auf NK Zellen Apoptose in HCV SGR Zellen auslösten. Für 
eine effiziente Eliminierung von HCV SGR Zellen waren jedoch Interaktionen zwischen pDCs, NK 
Zellen und Monozyten nötig, da isolierte Immunzellen HCV SGR Zellen nicht abtöten konnten. 
Obwohl die Expression der TRAIL Rezeptoren in HCV SGR Zellen und Huh-7 Kontrollzellen 
vergleichbar war, töteten durch HCV aktivierte PBMCs ausschließlich HCV SGR Zellen, nicht aber 
Huh-7 Kontrollzellen. Diese Spezifität konnte letztlich dadurch erklärt werden, dass HCV SGR 
Zellen per se sensibler gegenüber TRAIL induzierter Apoptose waren. 
Zusammenfassend wurde gezeigt, dass neben pDCs auch NK Zellen und Monozyten zur 
Immunantwort gegen HCV beitragen. Die wichtigsten Erkenntnisse sind die Beobachtungen, dass 
nur durch ein Zusammenspiel und gegenseitige Aktivierung von verschiedenen Zellen des 
angeborenen Immunsystems eine effiziente, schnelle und spezifische Immunantwort gegen HCV 
infizierte Zellen ausgelöst wird. 
 
Introduction 
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2 Introduction 
In our everyday life we are constantly challenged by various pathogens such as bacteria, 
viruses or fungi. It is the role of the immune system to recognize and combat those 
pathogens. In order to detect pathogens the immune system recognizes foreign structures 
which are different from the host (self versus non-self discrimination). The immune system 
consists of the innate and the adaptive immune system. The innate immune system is the 
first line of defense. It is specialized in detecting a broad range of so called pathogen 
associated molecular patterns (PAMPs) by pattern recognition receptors (PRRs)1. In 
consequence, the immune response elicited by the innate immune system is not specific 
for a certain pathogen, but a more general response. However, specialized antigen-
presenting cells (APCs) of the innate immune system are able to present foreign structures 
on their surface. Thereby, cells of the adaptive immune system are activated and initiate a 
specific response against the invading pathogen2. 
Infection immunology is the area of research that focuses on the interplay between 
pathogens and the immune system. For example, upon infection with the Hepatitis C virus 
(HCV) several foreign structures like viral nucleic acid and viral proteins are present in the 
host. These structures could be recognized by PRRs which would result in an immune 
response. In this work the ability of the innate immune system to detect HCV was 
investigated. Moreover, it was analyzed how different innate immune cells respond to the 
virus and how they interact in the anti-viral response. 
 
2.1  The Hepatitis C virus 
The Hepatitis C virus (HCV) is a member of the genus Hepacivirus, which belongs to the 
family of the Flaviviridae3. Infection with HCV implies a high risk for an establishment of a 
persistent infection. About 170 million people worldwide suffer from chronic HCV infection 
and are at high risk to develop liver cirrhosis and hepatocellular carcinoma4. As a 
consequence of these diseases caused by chronic HCV infection, approximately 350000 
people die annually5. 
HCV is an enveloped virus with an average diameter of 55 nm6. The enveloped capsid 
includes the genome of HCV, a positive single stranded (ss) RNA with a length of around 
9.6 kb. This RNA is flanked by 5’ and 3’ non-translated regions and contains an internal 
Introduction 
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ribosome entry site (IRES)7. Due to the IRES the viral RNA is targeted to ribosomes, which 
allows a cap-independent translation. From the genome a single polyprotein consisting of 
approximately 3000 amino acids is translated. This polyprotein is cleaved into 10 different 
proteins by viral and cellular proteases co- and post-translationally7,8: core, envelope 
protein 1 (E1), E2, p7, non-structural protein 2 (NS2), NS3, NS4A, NS4B, NS5A and 
NS5B. While the virus particle consists of the structural proteins core, E1 and E2, the non-
structural proteins are involved in replication and assembly and function as viral  
proteases9,10. The genome organization and polyprotein processing together with the 
function of individual proteins is shown in detail in Fig. 2-1.  
 
 
Fig. 2-1 The HCV genome and polyprotein organization 
The HCV genome is schematically depicted with the 5’ and 3’ non-translated regions (NCR). Domains II-IV of 
the 5‘ NCR form an internal ribosome entry site (IRES). The IRES in the 5’ NCR mediates translation of the 
HCV polyprotein precursor. The polyprotein is then processed co- and post-translationally into 10 proteins. 
Solid diamonds indicate cleavage sites of the HCV polyprotein precursor by an ER signal peptidase. The 
open diamond indicates further C-terminal processing of the core protein by signal peptide peptidase. Arrows 
indicate cleavages by the HCV NS2–3 and NS3–4A proteases. Below the single proteins are shown with 
their function and the general classification in structural and non-structural proteins is indicated. Adapted by 
permission from Macmillan Publishers Ltd: Nature Reviews Microbiology, Moradpour et al.
7
, copyright 2007. 
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2.1.1 HCV genotypes and treatment 
Due to its high genomic diversity HCV is classified into 7 genotypes (1-7). These 
genotypes differ in their nucleotide sequence by 30–35%. Within the genotypes further 
subtypes are described which show differences in their sequence by 20-25%11. The 
genetic diversity of HCV is a major problem for the development of a protective vaccine 
against HCV infection. In the past, HCV infected patients (independent of the genotype) 
were treated with a combination of polyethylene glycol-conjugated Interferon-α (IFNα) with 
the nucleoside analogue ribavirin12. This therapy led to sustained virologic response (SVR, 
defined by the absence of HCV RNA in serum 24 weeks after treatment had been 
stopped) rates of 70-80% for genotype 2 or 3, but lower rates for other genotypes13. Later, 
therapy for genotype 1 had been adjusted to a triple therapy. In addition to IFNα, inhibitors 
of viral proteases (e.g. Boceprevir and Telaprevir) were administered, which significantly 
increased the rates of SVR14. Drawbacks of this therapy were severe side effects. In the 
next stage, many new drugs against HCV were in clinical trials. In particular, IFNα free 
treatment was investigated whereby side effects could be limited15. Nowadays patients 
with HCV infection can be cured by a combination of the NS5B inhibitor Sofosbuvir and the 
NS5A inhibitors Daclatasvir and Ledipasvir16. However, medication to prevent infections 
(e.g. vaccination) is not available. 
 
2.1.2 HCV life cycle 
HCV attaches to the host cell (hepatocytes) by binding to various receptors on the host cell 
surface. These are scavenger receptor-BI (SR-BI)17, the tetraspanin co-receptor CD8118 
and the tight junction proteins Claudin19 and Occludin20. Via clathrin-mediated endocytosis  
the virus then is internalized by host cells21. Inside the cell, viral RNA is released to the 
cytoplasm in a pH-dependent manner22 and as described before can be translated directly 
due to its IRES. After expression of viral proteins, non-structural proteins rearrange ER 
membranes in the host cell. Thereby, a so called membranous web is formed, where viral 
replication is supposed to take place 23. Initially, from the positive ssRNA genome a 
complementary negative strand is synthesized. Thus, double-stranded (ds) RNA occurs as 
a replication intermediate 24. Likewise, also negative ssRNA is considered as a replication 
intermediate, as it serves as a template for synthesis of positive ssRNA. In turn, the 
progeny positive ssRNA is then used for further cycles of replication and translation or is 
Introduction 
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packaged into newly assembled virus particles. Viral particles exit the cell by highjacking 
the very low density lipoprotein (VLDL) pathway. 
 
2.1.3 Fate of viral replication intermediates 
As described before during HCV replication negative ssRNA and dsRNA occur as 
replication intermediates and both are potential activators of innate immunity (see 2.3.2). 
Interestingly, it has been observed that the ratio of positive and negative ss viral RNA is 
kept at a constant level25. Since viral positive ssRNA has a reported half-life between 11-
14 h26 also replication intermediates must be turned over to retain the constant ratio. 
However, it is currently unknown how turnover of these replication intermediates takes 
place. Unpublished data of AG Lohmann (Molecular Virology, Heidelberg) provide 
evidence that besides positive ssRNA27 also negative ss viral RNA is secreted by HCV 
SGR cells. Thus, secretion seems to be a mechanism contributing to turnover of viral 
replication intermediates. Moreover, secretion of replication intermediates might contribute 
to immune evasion in the infected cell. In turn, release of viral RNA could also lead to 
activation of professional immune cells (see 2.3.2). 
 
2.2  The Replicon System 
For detailed studies of the intracellular stage of viruses the establishment of a permissive 
cell-culture system is a prerequisite. A milestone in the development of HCV cell culture 
systems was the development of subgenomic replicons (SGR)28. SGR are lacking the 
structural proteins. Hence, no virus particles can be formed. Instead they carry a specific 
resistance gene, allowing selection of the cells in which the SGR replicates. Moreover, 
SGRs contain an IRES of the encephalomyocarditis virus. This IRES allows translation of 
HCV proteins, while the HCV IRES directs translation of the resistance gene. The 
schematic setup of the SGR is shown in Fig. 2. 
Most importantly, SGR are able to replicate autonomously after transfection into Huh-7 
cells. Huh-7 is a human hepatoma cell line29. Interestingly, upon infection of Huh-7 cells 
with HCV no interferons are produced30 (see below for immune escape mechanisms of 
HCV). Efficiency of replication for these SGR derived from genotype 1b (Con1 isolate) was 
increased by cell culture adapted mutations31. Later, a SGR from genotype 2a background 
Introduction 
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(JFH isolate) was found that replicated efficiently without the need of cell culture adaptive 
mutations32. Moreover, by introduction of a Luciferase gene into SGR, a tool was 
developed to easily monitor replication of the SGR by luciferase assays33.  
 
Fig. 2-2 Schematic organization of HCV subgenomic replicons 
In (a) the HCV genome consisting of 5’ and 3’ non-translated regions (NTR), an internal ribosome entry site 
(IRES), structural proteins (blue) and non-structural proteins (red) is depicted. In (b) a subgenomic replicon is 
shown, in which the structural proteins were replaced by a neomycin phosphotransferase gene (neo) and an 
IRES of another virus (encephalomyocarditis virus; EMCV). This IRES directs the expression of the HCV 
non-structural proteins, whereas the selectable marker neo is translated under the control of the HCV IRES 
that is present in the 5' non-translated region (NTR). Adapted by permission from Macmillan Publishers Ltd: 
Nature Reviews Drug Discovery, Bartenschlager et al.
34
, copyright 2002. 
 
2.3  Innate Immunity and HCV  
2.3.1  The role of innate immunity 
The innate immune system is the first line of defense against invading pathogens. It exerts 
a rapid, but rather unspecific response upon detection of a pathogen. Players of the innate 
immune system comprise physical factors (e.g. barrier of epithelial cell layers or mucus), 
the complement system as the humoral part and different cells such as granulocytes, 
natural killer cells (NK cells), monocytes and macrophages or dendritic cells (DCs). One 
function of innate immunity is to directly combat pathogens by different effector 
mechanisms (e.g. phagocytosis or cytokine production). Another important role is the 
activation of the highly specific adaptive immune response. Antigen-presenting cells 
(macrophages, DCs) present microbial components on their surface, where they are 
recognized by T lymphocytes. Especially DCs play an important role in this process, since 
naïve T-cells can on only be primed by DCs. 
Introduction 
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2.3.2  Pattern recognition receptors of viral RNA 
In general, a prerequisite for initiation of an innate immune response is the recognition of 
pathogen-associated molecular patterns (PAMPs) by pattern recognition receptors 
(PRRs)1. PAMPs are evolutionary conserved molecules, which are essential for microbial 
fitness. PRRs specifically recognize these conserved structures, which are absent in the 
host. Thereby, PRR distinguish between self and non-self. Next to PAMPs, also 
endogenous molecules, so called danger-associated molecular patterns (DAMPs) are 
recognized by PRRs35. For example, ATP under physiological conditions is only found 
inside of cells. Occurrence of extracellular ATP mediates a danger signal and ATP acts as 
a DAMP to activate immune cells36. 
Among the PRRs, certain Toll-like receptors (TLRs) and retinoic acid-inducible gene-I 
(RIG-I)-like receptors (RLRs) are detectors of viral RNA. TLRs that recognize nucleic acids 
are present in endosomes in order to avoid self-recognition. Essential for trafficking of 
endosomal TLRs from the ER to endosomes is the chaperone Unc93b137. RLRs are 
present in the cytosol. TLR3 recognizes double stranded RNA38, TLR 7 and 8 single 
stranded RNA39,40 and RIG-I double stranded RNA or single stranded RNA with a 5’ 
triphosphate41,42. Further RLRs detecting double stranded RNA are MDA5 and LPG2. 
Indeed, TLR7 and TLR8 polymorphisms43,44 have been shown to play a role in HCV 
progression and RIG-I was shown to detect HCV RNA45. 
Although these receptors have specific signaling pathways, all can result in the expression 
of Interferon Regulatory Factors (IRFs). IRFs in turn drive expression of type I interferons 
(reviewed in46). IFNα and IFNβ are the most important type I interferons in viral defense. 
Upon binding of type I interferons to their respective receptor, a JAK-STAT signaling 
cascade is initiated which leads to expression of many IFN-stimulated genes (ISG). The 
concerted action of ISGs sets up an anti-viral state in which multiple anti-viral mechanism 
are employed47. 
However, pathogens have evolved mechanisms of immune evasion. HCV inhibits an 
immune response of the infected cell by cleaving MAVS (synonym for Cardif, VISA or IPS-
1), an important adaptor molecule in RLR signaling, by its NS3/4A protease48. 
Furthermore, the NS3/4A protease also cleaves TRIF, an adaptor molecule in the TLR3 
signaling pathway49. With these mechanism of immune evasion the production of type I 
interferons is strongly inhibited in HCV infected hepatocytes. However, an induction of 
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ISGs has been observed in HCV infected livers50,51. In consequence, it was hypothesized 
that interferons are produced by cells that are not infected by HCV. As HCV predominantly 
infects hepatocytes, immune cells were considered to be responsible for secretion of 
interferons. The role of innate immune cells in interferon secretion in response to HCV will 
be described in the following. 
 
2.3.3 Plasmacytoid DCs and HCV 
A specialized innate immune cell that produces high amounts of IFNα and IFNβ upon 
stimulation is the plasmacytoid dendritic cell (pDC)52. pDCs are a specific subset of 
dendritic cells that circulate through the blood and can be recruited to tissues. They 
express TLR7 and TLR953,54. While TLR9 recognizes CpG rich DNA, TLR7 detects single 
stranded RNA and therefore might sense HCV RNA. Indeed, it has been shown that pDCs 
are present in high amounts in HCV infected livers55. However, some reports indicated an 
impaired function of pDCs upon HCV infection56,57. It was observed that patients with 
chronic HCV infection had reduced numbers of pDCs in the blood, that pDCs were less 
efficient in activation of CD4 T-helper cells and that pDCs secreted less IFNα. 
Nevertheless, other groups could show that HCV triggers IFNα production by pDCs. At first 
Gondois-Rey et al. described a weak activation of pDCs by HCV in comparison with 
influenza and herpes virus58. Later Takahashi et al. provided further evidence that pDCs 
sense HCV infected cells in co-culture experiments and produce large amounts of IFNα via 
TLR7 signaling59. Interestingly, this group observed that pDCs are also stimulated when 
co-cultured with HCV SGR cells instead of virus infected cells, but HCV virions alone did 
not stimulate pDCs. In consequence, it was speculated that active viral replication and cell-
cell contacts between pDCs and HCV SGR cells were required for IFNα secretion by 
pDCs. Thus, this study provided evidence that ISG up-regulation in HCV infected livers is 
driven by IFNα secreted by pDCs. 
The observation that pDCs were stimulated in co-culture raised the question how viral 
RNA is accessing pDCs. It is known that HCV SGR cells secrete viral positive ssRNA 
protected by membranes, although due to the lack of structural proteins no virus particles 
can be formed27. Furthermore, the finding that plasma from HCV patients contains 
exosomes associated with viral RNA60 hinted towards a possible role of exosomal 
transport of viral RNA from infected cells to pDCs. Exosomes are 40-100 nm small 
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vesicles which are formed by an endocytosis event in late endosomes, which are then 
called multi vesicular bodies (MVB). Fusion of these MVB with the plasma membrane 
releases exosomes from the cell and many cell types are known to secrete exosomes (a 
detailed review of exosomes can be found in61). Since their discovery many roles of 
exosomes have been described. The most important role in this context is the transport of 
RNA between different cells62. It was shown that within the above described co-culture 
experiments a “short range transfer” of exosomes released from SGR cells triggered a 
response of pDCs via TLR7 signaling63. It was further shown that this transfer was 
dependent on the endosomal sorting complex required for transport (ESCRT) machinery, 
which was described to be involved in exosome formation64–66. Moreover, it was observed 
that expression of Annexin A2 (ANXA2) in hepatocytes was essential for pDC activation. 
ANXA2 was described to bind to RNAs67,68 and to be required for vesicle trafficking and 
generation of MVBs69–71. It has also been linked to production of HCV virions72 and to 
participate in the formation of HCV replication complexes73. In summary, the study by 
Dreux et al. described a route of transfer of viral RNA from infected cells into pDCs via 
“short range transfer” of exosomes 63. 
 
2.3.4 Monocytes and HCV 
Similar to pDCs, monocytes are part of the cellular innate immune system. They circulate 
through the blood and can be recruited to tissues upon infection. Within the population of 
peripheral blood mononuclear cells (PBMCs), monocytes can be detected by the 
expression of their surface marker CD1474. They are further subdivided into 3 populations 
based on the expression levels of CD1675 and each population accounts for different 
functions (reviewed in76). Classic effector mechanisms of monocytes are the phagocytosis 
of bacteria and the secretion of pro-inflammatory cytokines77. Upon extravasation from the 
blood into tissues monocytes differentiate into macrophages78. Of note, tissue specific 
macrophages can also be generated during embryonic development (reviewed in79). 
Macrophages in addition act as antigen-presenting cells, thereby bridging innate and 
adaptive immunity. 
Monocytes in theory could also be able to detect HCV RNA as monocytes express TLR880, 
which as described above recognizes ssRNA. However, thus far no evidence exists that 
monocytes respond to HCV RNA. In general, not much is known about the contribution of 
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monocytes in the anti-viral response against HCV. Over a long time research on the role of 
monocytes in HCV infection focused on the question if monocytes and macrophages can 
be infected by HCV, which is still discussed controversially (reviewed in81). Later, one 
study then showed that monocytes are able to sense HCV infected cells and to induce a 
response82. This study demonstrated that monocytes show inflammasome activation upon 
sensing HCV infected cells, but the underlying mechanism was not investigated. 
Moreover, it was shown that monocytes secreted TNFα and that inflammasome activation 
led to secretion of IL-18. These functions were impaired in monocytes from HCV infected 
patients. While TNFα had a direct effect on viral replication, IL-18 activated NK cells. IFNγ 
secretion by NK cells then in turn further boosted the anti-viral response. Thus, this study 
provided evidence that monocytes play a role in the immune response against HCV. 
Second, the results hinted towards an interplay between innate immune cells in the anti-
viral response. 
 
2.3.5 NK cell effector mechanisms 
Despite being classified as lymphocytes, NK cells functionally belong to the cells of the 
innate immune system since they do not express antigen specific receptors. As their name 
“natural killer cells” already implies, they are specialized in killing virus infected cells83,84 
and tumor cells 85,86. Tumor cells lacking MHC class I expression can be targeted by NK 
cells87, as explained by the missing self hypothesis. In contrast to the above described 
active recognition of foreign structures by PRRs, NK cells can also be activated by the 
absence of “self” structures. Nowadays it is understood, that NK cell activation depends on 
recognition of various activating and inhibitory ligands (detailed review in88). NK cells can 
target cells by three different effector mechanisms. First, NK cells are able to secrete 
IFNγ89. Thereby, ISGs are up-regulated in target cells and viral infection is hampered47. 
Second, NK cells can kill target cells by secretion of cytotoxic granules90. These granules 
are similar to the granules released by cytotoxic T-killer cells and contain perforin and 
granzyme (reviewed in91). Third, by up-regulation of apoptosis inducing ligands like Fas 
ligand (FasL) and tumor-necrosis factor-related apoptosis-inducing ligand (TRAIL) NK cells 
can drive apoptosis of target cells. TRAIL is a member of the TNF family92 and can bind to 
different receptors. These receptors can be classified in pro- or anti-apoptotic receptors. 
While binding of TRAIL to DR493 or DR594 induces apoptosis, binding to DcR195 or DcR296 
protects from apoptosis, as these receptors lack intracellular signaling domains. In 
Introduction 
22 
 
contrast, DR4 and DR5 have an intracellular death domain. Upon TRAIL binding, 
homotrimers of the receptors are formed97 and clusters of death domains are built. The 
adaptor protein Fas-associated death receptor (FADD) is recruited to this cluster, and in 
turn recruits caspase-8 and caspase-10. This leads to successive caspase activation via 
caspase-8, caspase-10, caspase-6, caspase-7 and caspase-3. Detailed reviews about the 
apoptotic signaling including several other players are given in Wang et al.98 and in 
Gonzalvez et al.99. Caspase-3 finally cleaves numerous cellular proteins to initiate the 
programmed cell death of apoptosis. Among others, poly(ADP-ribose) polymerase (PARP) 
is cleaved by caspase-3 which determines the final irreversible step of apoptosis100. 
 
2.3.6 NK cells and HCV 
NK cells were also described to play a role in the anti-viral response against HCV. Over 10 
years ago it was reported that NK cells activated by cytokines can kill HCV SGR cells101. 
Later it was shown that IFNγ is secreted by NK cells in an HCV context. However, IFNγ 
secretion by NK cells was shown to be dependent on pDCs102. It was observed that in the 
co-culture of HCV SGR cells with PBMCs IFNγ was secreted and it was proven by flow 
cytometry that NK cells were the source of IFNγ. Of note, no IFNγ was secreted by purified 
NK cells in response to HCV SGR cells. Further experiments demonstrated that IFNα 
secretion by pDCs was essential for NK cell activation and that monocyte-derived IL-15 
was needed for maximal IFNγ production. Interestingly, although they observed a role of 
cytokines in NK cell activation it was also shown that NK cells required contacts to other 
cells. However, it was not clear, if contacts with HCV SGR cells, with other immune cells or 
with both were necessary for NK cell activation. In contrast, another study described a 
predominant role for monocytes in NK cell activation82. As described above (see 2.3.4) this 
study showed that monocyte derived IL-18 triggered IFNγ secretion by NK cells, while 
pDCs had no influence. 
Moreover, it has been described that IFNα in HCV infection can result in TRAIL expression 
on NK cells103,104. In the first study it was observed that chronic HCV infection increased 
the percentage of TRAIL positive NK cells, especially for NK cells in the liver compared to 
NK cells in the blood. Therefore, it was hypothesized that IFNα secretion in the liver might 
account for TRAIL expression on NK cells. Indeed they could show that in vitro stimulation 
of NK cells from healthy donors and from HCV patients with IFNα led to TRAIL expression 
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on NK cells. Stegmann et al. in the second study stimulated PBMCs from healthy donors 
with IFNα and found by microarray analysis that TRAIL was strongly up-regulated in NK 
cells. Similar to the first study they also stimulated NK cells from HCV patients with IFNα in 
vitro and as well observed an up-regulation of TRAIL. Interestingly, NK cells from patients 
that responded to IFNα therapy also displayed stronger TRAIL expression after in vitro 
stimulation with IFNα. Thus, the authors concluded that TRAIL expression on NK cells can 
control the virus. 
In summary, these findings suggested that next to pDCs and monocytes also NK cells 
contribute to the anti-viral response against HCV. Importantly, in all studies NK cell 
activation was reported to be dependent on other innate immune cells like pDCs and 
monocytes. Hence, it became clear that innate immune cells interact with each other in the 
course of HCV infection. While previous studies mainly focused on the influence of 
monocytes and pDCs on NK cells, it was hypothesized that additional interactions between 
innate immune cells could boost the anti-viral response. Thus, in this work the analysis of 
the interaction and mutual activation between innate immune cells was a central part. 
 
2.4 Objectives of this study 
The aim of this work was to analyze the activation of innate immune cells by viral RNA 
secreted from HCV SGR cells. First, a co-culture of HCV SGR cells with PBMCs should be 
established to reproduce the findings that IFNα is produced in this co-culture. In the 
following this activation process should be further investigated. In detail, it should be 
investigated if recognition of viral RNA in fact is the trigger for activation of innate immune 
cells. Moreover, this study was planned to provide further evidence how viral RNA is 
transported from HCV SGR cells into immune cells. Thus, the role of exosomal transport of 
viral RNA and via direct cell-cell contact should be examined. 
In addition, it was planned to further analyze if also other innate immune cells next to 
pDCs participate in the response against HCV. Literature provided first indications that 
also monocytes and NK cells play a role in the anti-viral response against HCV. Hence, 
this work should give deeper insights about their contribution. In particular, also the 
interaction between different innate immune cells in the response against HCV should be 
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addressed. The focus here laid on the question if a possible interaction and mutual 
activation of innate immune cells leads to a stronger and more efficient response. 
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3 Materials & Methods 
3.1  Materials 
3.1.1  Devices & Instruments 
Device    Type & Manufacturer 
AutoMACS    Miltenyi Biotec, Bergisch-Gladbach  
Balance    EW600-2M, Kern & Sohn GmbH, Balingen  
Blotting chambers    Transfer chamber/ Biometra, Jena 
Centrifuges Multi 3 S-R, Heraeus Instruments; Hanau Fresco17, Thermo 
Scientific, Karlsruhe  
Counting chamber   Neubauer 0.00025 mm2/0.1 mm, Brand GmbH, Schwerin 
Fine balance    MC1 Research RC 210 P, Wiegetechnik Knoll, Ketsch 
Flow cytometer   BD FACSCantoTM, BD Biosciences, San Diego, USA 
Heating blocks    AccuBlock, Eppendorf, Hamburg 
ImageStream    IS100, Amnis, Merck Millipore, Darmstadt 
Incubator    BBD6226, Heraus Instruments, Hanau 
Luminometer    Mithras LB 940, Berthold technologies, Freiburg 
Mass Spectrometer   Q-Exactive HF MS, Thermo Fisher Scientific, Waltham, USA 
Microscope     Leica DM-LS, Leica GmbH, Wetzlar 
Microtiter plate photometer  SUNRISE Absorbance Reader, Tecan, Salzburg, Austria 
Orbital shaker    Labortechnik Fröbel GmbH, Lindau 
pH-Meter    Seven Easy, Mettler Toledo, Gießen 
Power supply     Power Pac HC, BioRad, München 
Q-Exactive HF MS   Thermo Scientific, Karlsruhe 
qPCR cycler    StepOne Plus, Applied Biosystems, Darmstadt  
SDS-PAGE system    perfectBlue™ Twi S, Peqlab, Erlangen 
Spectrophotometer   NanoDrop®ND-1000, Peqlab, Erlangen  
Sterile bench     Hera Safe KS 12, Heraeus Instruments, Hanau 
SW28 rotor     Beckman-Coulter, Krefeld 
Thermocycler    Primus advanced 96, Peqlab, Erlangen  
Vortexer    MS 1, IKA®Works, Inc., Wilmington, USA 
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3.1.2  Consumables 
Consumables   Manufacturer 
24-well cell culture plate  Greiner Bio-One, Frickenhausen 
48-well cell culture plate  Corning Incorporated, Corning, USA 
96-well cell culture plate  Greiner Bio-One, Frickenhausen 
Blotting membrane    Immobilon-P Transfer, Millipore Billerica, USA 
Blotting paper    Whatman® GB003, Whatman GmbH, Dassel 
cDNA tubes    PP-PCR-tubes, Greiner Bio-One GmbH, Frickenhausen  
Cell culture plates   Greiner Bio-One, Frickenhausen 
Cell scraper    Greiner Bio-One, Frickenhausen  
ELISA plates    96 well, Greiner Bio-One GmbH, Frickenhausen  
Eppendorf tubes   Eppendorf AG, Hamburg  
FACS tubes    BD FalconTM 5 ml, BD Biosciences, Heidelberg  
Falcon tubes    Greiner Bio-One, Frickenhausen 
Gauge needles   MicrolanceTM 3, 27G, BD Biosciences, Heidelberg 
Optical Adhesive Cover   Absolute QPCR Seal, ABgene House, Epsom, UK 
Petri dishes    Greiner Bio-One, Frickenhausen 
Pipette tips     Hinged Rack Pipette tips, Corning, New York, USA 
qPCR plates MicroAmp, Fast 96-well reaction plate (0.1 ml), 
AppliedBiosystems, UK 
Syringe     BD Discardit II 27G, 10ml, BD Biosciences, Heidelberg  
Transwell inserts    1 µm pore size, 24 well, Corning Incorporated, Corning, USA 
 
3.1.3  Chemicals & Reagents 
Chemical / Reagent  Manufacturer 
Acrylamide, stock solution (30%) Roth GmbH, Karlsruhe 
Ammonium persulphate (APS)  Sigma-Aldrich, Taufkirchen 
Aqua ad injectabila   Braun, Melsungen  
Blasticidin    Sigma-Aldrich, Taufkirchen 
Bovine serum albumin (BSA) Sigma-Aldrich, Taufkirchen 
Brefeldin A    Sigma-Aldrich, Taufkirchen 
Bromphenol blue    Sigma-Aldrich, Taufkirchen 
Carboxyfluorescein succinimidyl  Sigma-Aldrich, Taufkirchen 
ester (CFSE) 
Coomassie Brilliant Blue R-250 Thermo Scientific, Karlsruhe 
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CytoTell™ Red 650   AAT Bioquest, Sunnyvale, USA 
Dimethylsulfoxide (DMSO)  Sigma-Aldrich, Taufkirchen 
Dithiothreitol    Sigma-Aldrich, Taufkirchen 
DMEM     Biochrom AG, Berlin 
Enhanced chemiluminescence  PerkinElmer, Rodgau 
(ECL) substrate  
Ethanol    Sigma-Aldrich, Taufkirchen 
FACSClean™    BD Bioscience, Heidelberg 
FACSFlow™     BD Bioscience, Heidelberg 
Fetal calf serum (FCS)  GibcoTM, Invitrogen, Karlsruhe  
FL2 in vitro transcript   G. Stöcklin, DKFZ Heidelberg 
G418     Life Technologies, Darmstadt 
Heparin Solution    StemCell Techonolgies, Köln 
Hygromycin B    Life Technologies, Darmstadt 
Isopropanol     Riedel-de Haën AG, Seelze 
L-glutamine    Life Technologies, Darmstadt 
Lipofectamine RNAiMAX  Life Technologies, Darmstadt 
MACS buffer    Miltenyi Biotec, Bergisch-Gladbach  
Methanol     Riedel-de Haën AG, Seelze 
OptiMEM     Invitrogen, Karlsruhe 
Pancoll    PAN-Biotech GmbH, Aidenbach 
PBS     PAA Laboratories, Pasching, Austria  
Penicillin/Streptomycin (100x)  Sigma-Aldrich, Taufkirchen 
Penicillin/Streptomycin solution PAA Laboratories, Pasching, Austria  
Puromycin    Sigma-Aldrich, Taufkirchen 
RPMI     Biochrom AG, Berlin 
Saponin    Carl Roth GmbH, Karlsruhe 
Sodiumchloride   AppliChem GmbH, Darmstadt 
Sodiumdihydrogenphosphate AppliChem GmbH, Darmstadt 
Sodiumdodecylsulfate (SDS) AppliChem GmbH, Darmstadt 
Sodiumphosphate    Merck, Darmstadt 
Sulfuric acid    VWR International S.A.S, Fontenay-sous-Bois, France 
TEMED     Sigma-Aldrich, Taufkirchen 
Trypan blue    Sigma-Aldrich, Taufkirchen 
Trypsin/EDTA    PAA Laboratories, Pasching, Austria  
Tween-20    Sigma-Aldrich, Taufkirchen 
β-mercaptoethanol   Sigma-Aldrich, Taufkirchen 
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3.1.4  Kits 
Chemical / Reagent  Manufacturer 
BD OptEIATM human IL-6 ELISA set   BD Biosciences, Heidelberg  
BD OptEIATM human IL-6 ELISA set   BD Biosciences, Heidelberg  
BD OptEIATM murine IL-6 ELISA set  BD Biosciences, Heidelberg  
CD14 Microbeads isolation kit   Miltenyi Biotec, Bergisch-Gladbach  
CD304 Microbeads isolation kit   Miltenyi Biotec, Bergisch-Gladbach  
CD56 Microbeads isolation kit   Miltenyi Biotec, Bergisch-Gladbach  
Cytotoxicity Detection Kit Plus (LDH)  Roche Diagnostics, Mannheim 
Fast SYBR green master mix   Applied Biosystems, Darmstadt 
High capacity cDNA reverse transcription kit AppliedBiosystems, Darmstadt 
IFNα ELISA kit human    eBioscience, Frankfurt 
IFNγ ELISA kit human    eBioscience, Frankfurt 
NucleoSpin® RNA kit     Macherey-Nagel, Düren 
PageRuler™Prestained Protein Ladder Plus Fermentas, St. Leon-Rot 
PeqGold Total RNA Kit     Peqlab Biotechnology GmBH, Erlangen 
Pierce Cell Surface Protein Isolation Kit  Thermo Scientific, Karlsruhe 
 
3.1.5  Buffers and solutions 
Buffer    Reagent Concentrations 
10x PBS 80 mM di-sodiumhydrogenphosphate; 20 mM sodium di-
hydrogenphosphate; 1.4 M NaCl; pH 7.4 
10x TBS    100 mM Tris-HCl, pH 8.0; 1.5 M NaCl 
1x TBST    1xTBS, 0.05% (v/v) Tween-20 
4x SDS PAGE sample buffer 40% (w/v) glycerol, 8% (w/v) SDS, 400 mM (v/v) β-
mercaptoethanol, 200 mM Tris-HCl (pH 8.8), 0.4% (w/v) 
bromophenolblue 
ELISA blocking buffer (IFNα)  1 x PBS, 0.5% (w/v) BSA, 0.05% (v/v) Tween-20 
ELISA blocking buffer  1x PBS; 10% (v/v) FCS 
ELISA coating buffer   0.1 M sodiumcarbonate, pH 9.5 
ELISA washing buffer  1x PBS; 0.05% (v/v) Tween-20 
FACS buffer    1x PBS, 2% (v/v) FCS 
Luciferase assay buffer 25 mM glycyl-glycin (pH 7.8), 15 mM potassium phosphate 
buffer (pH 7.8); 15 mM MgSO4; 4 mM EGTA, 1 mM DTT, 2 
mM ATP and 0.07 mM luciferin 
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Luciferase lysis buffer  1% Triton X-100; 25 mM glycyl-glycin (pH7.8); 15 mM MgSO4; 
4 mM EGTA; 10% glycerol, 1 mM DTT 
Pen/Strep(100x)   10.000 U/ml penicillin G; 10 mg/ml streptomycin; 
0.9% (w/v) NaCl  
Permeabilization buffer  1x FACS buffer; 0.1% saponin 
SDS-PAGE Running buffer   25 mM TRIS-OH (pH 8.3), 192 mM Glycin,  
10% (v/v) Methanol 
Semidry blotting buffer   25 mM Tris-OH (pH 8.3), 192 mM Glycin, 10% (v/v) Methanol 
Separating gel buffer   1.5 M Tris-HCl (pH 8.8), 0.4% (w/v) SDS 
Stacking gel buffer    1 M Tris-HCl (pH 6.8), 0.8% (w/v) SDS 
Trypan blue solution   2 mg/ml trypan blue in 1x PBS  
Trypsin solution   0.05% trypsin; 0.02% EDTA in 1x PBS 
 
 
3.1.6  Primers for qPCR 
Target  Forward (5`to 3`)    Reverse (5`to 3`) 
DcR1   TACCACGACCAGAGACACC   CAGTGGTGGCAGAGTAAGC 
DcR2   TACCACGACCAGAGACACC   CACCCTGTTCTACACGTCCG 
DR4   AGAGAGAAGTCCCTGCACCA   GTCACTCCAGGGCGTACAAT 
DR5   AAGACCCTTGTGCTCGTTGT   AGGTGGACACAATCCCTCTG 
FL2    ATCACAGAATCGTCGTATGC   CATACTGTTGAGCAATTCACG 
HCV    CGGTTCTTTTTGTCAAGACC   GAGCAAGGTGAGATGACAG 
IL-8   CAAGAGCCAGGAAGAAACCA    GCAAAACTGCACCTTCACAC 
IP-10   GGTCTGAGTGGGACTCAAGG   GTGGCAATGATCTCAACACG 
MCP-1   ATAGCAGCCACCTTCATTCC   CAGATCTCCTTGGCCACAAT 
MIP-1α  AGTTCTCTGCATCACTTGCTG   CGGCTTCGCTTGGTTAGGAA 
MIP-1β  CTGTGCTGATCCCAGTGAATC   TCAGTTCAGTTCCAGGTCATACA 
Rab27a  GGAGAGGTTTCGTAGCTTAACG  CCACACAGCACTATATCTGGGT 
β-actin   GGCTCCGATATCTCTGTCGT    ATGTTGCATTTCGTCACACC 
 
3.1.7  Antibodies 
Target  Application  Manufacturer   Ref.nr. 
IFNα   Neutralization  PBL, Piscataway, USA  21112-1 
IgG1    Neutralization  Acris, San Diego, USA  AM03095PU-N 
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CD81   Blocking  BD Biosciences, Heidelberg  555675 
CD9    Blocking  BD Biosciences, Heidelberg  555370 
IgG1   Blocking  BD Biosciences, Heidelberg  555746 
TRAIL   Blocking  BD Biosciences, Heidelberg   550912 
Cleaved PARP WB   Cell Signaling, Frankfurt  #9541 
β-actin   WB   Cell Signaling, Frankfurt   #4970 
Anti-Rabbit IgG  WB   Cell Signaling, Frankfurt  #7074 
CD14 APC  FC   BD Biosciences, Heidelberg   555399 
CD14 PE  FC   BD Biosciences, Heidelberg   562691 
CD25 PerCP Cy5.5 FC   Biolegend, San Diego, USA  356112 
CD3 FITC   FC   BD Biosciences, Heidelberg  555332 
CD3 FITC   FC   BD Biosciences, Heidelberg  555332 
CD3 APC Cy7 FC   BD Biosciences, Heidelberg  557832 
CD38 APC  FC   BD Biosciences, Heidelberg  555462 
CD44 FITC  FC   BD Biosciences, Heidelberg  555478 
CD56 APC   FC   Miltenyi Biotec, Bergisch-Gladbach 130-090-843 
CD56 Pe Cy7  FC   eBioscience, Frankfurt  25-0567-42 
CD69 APC   FC    BD Biosciences, Heidelberg   555533 
CD80 PE   FC   BD Biosciences, Heidelberg   557227 
CD86 PE   FC   BD Biosciences, Heidelberg   555665 
IL-8 APC  FC   eBioscience, Frankfurt  17-8088 
TRAIL PE   FC   BD Biosciences, Heidelberg  550516 
 
3.1.8  Inhibitors & Stimuli 
Inhibitor / Stimulus  Manufacturer 
Bafilomycin    Calbiochem, Darmstadt 
Chloroquine    Sigma-Aldrich, Taufkirchen 
CpG1668    Invivogen, Toulouse, France 
GW4869    Cayman Chemical, Ann Arbor, USA 
IFNα     Peprotech, Hamburg 
IFNγ     Peprotech, Hamburg 
Lipopolysaccharide (LPS)  purified from S. minnesota, kind gift from U. Seydel, Borstel  
R848     Invivogen, Toulouse, France 
Spiroepoxide    Santa Cruz Biotechnology, Dallas, USA 
TNFα     Peprotech, Hamburg 
TRAIL     eBioscience, Frankfurt 
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Z-IETD-FMK    Enzo Life Sciences, Lausen, Switzerland 
Z-VAD-FMK    Invivogen, Toulouse, France 
Z-YVAD-FMK    Enzo Life Sciences, Lausen, Switzerland 
 
3.1.9 siRNA 
Target    Sequence (5`to 3`)  
Rab27a    GCUGCCAAUGGGACAAACA (dTdT) 
GFP     GCAAGCUGACCCUGAAGUUCAU 
 
3.1.10 Cells 
Cells indicated to carry viral RNA were transfected with a SGR of the given genotype. Cells without 
reference were produced by AG Lohmann. 
Cell line HCV genotype selection   details 
Huh-7  -   -    human hepatoma cell line29 
Huh-7   HCV 2a  1 mg/ml G418   described in32 
JFH1 
Huh-7   HCV 1b  1 mg/ml G418   described as Huh-7 9-13 in28 
Con1 
Huh-7cured  -   -    cured by IFN treatment  
Con1        as described in 105 
Huh-7 Con1 HCV 1b  1 mg/ml G418   mutation affects replication  
S2204R        efficiency 
Huh-7 Con1 HCV 1b  1 mg/ml G418   mutation affects replication  
K1846T        efficiency 
Huh-7 Con1 HCV 1b  1 mg/ml G418   mutation affects replication  
E1202G+         efficiency 
T1280S+ 
K1846T 
Huh-7 DV  -   75 μg/ml Hygromycin B described in106 
Huh-7 HAV  -   2.5 μg/ml of Blasticidin described in107 
Huh-7  HCV 2a  1 mg/ml G418   viral RNA carries Luciferase 
Luc JFH        gene33 
 
Huh-6  -   -    human hepatoblastoma cell108  
Huh-6   HCV 1b  0.5 mg/ml G418  described in109 
Con1 
Huh-6   HCV 2a  0.5 mg/ml G418  A. Cerwenka (DKFZ, Heidelberg) 
JFH  
Huh-6 cured -   -    cured by IFN treatment, 
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JFH         A. Cerwenka (DKFZ, Heidelberg) 
Huh-7.5 -   -    described in 110 
Hep56D -   -    murine hepatoma cell line111 
Hep56D  HCV 2a  0.5 mg/ml G418,  
JFH1     5 µg/ml Blasticidin 
 
3.1.11 Mouse strains 
Wildtype C57BL/6 mice were purchased from Charles River Laboratories (Wilmington, USA). TLR7 
KO mice were obtained from Stefan Bauer (University Marburg). Unc93b1 mutant mice harboring 
an H412R missense mutation37 were received from the Max Planck Institute (Freiburg). Mice were 
bred under specific pathogen free (SPF) conditions. Breeding and monthly control for infections 
was performed according to the FELASA and GV-SOLAS guidelines 2014. Killing and dissection of 
mice was approved by the local authorities (Regierungspräsidium Karlsruhe) and experiments 
were properly recorded.  
Mice were hold in small groups of 2-8 animals (Makrolon cages of type II and III) under SPF 
(specific pathogen free) conditions. They were kept in air-conditioned rooms (20-22°C) with a day-
night cycle of 12 h each. Water and standardized food (pellet food Rod18 from Las Vendi) were 
available ad libitum. All mice were put in new cages at least once per week. Female mice with 
new-born pups were put in new cages twice per week after pups were one week old. Additionally, 
pelleted breeding food was applied to the the bottom of the cages. 
 
3.1.12 Software 
Software    Manufaturer 
FACSDivaTM    BD Bioscience, San Diego  
GraphPad Prism version 6.00  GraphPad Software Inc., San Diego, USA  
IDEAS version 6.0   Amnis, Merck Millipore, Darmstadt 
ImageJ    National Institutes of Health, Bethesda, USA 
Inkscape 0.48    Free Software Foundation Inc., Boston, USA 
Magellan (ELISA reader)   Tecan, Salzburg, Austria 
NanoDrop 3.0.1    Nanodrop Technologies, Rockland, USA 
Perseus     Jürgen Cox, MPI of Biochemistry, Martinsried 
R     R Foundation for Statistical Computing, Vienna, Austria) 
StepOne™ Software v2.1  Applied Biosystems, Darmstadt 
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3.2 Methods 
3.2.1 Cell culture  
3.2.1.1 Cell lines 
All cells (see 3.1.10) were cultured in Dulbecco’s modified eagle medium (DMEM) 
supplemented with 10% fetal calf serum (FCS), 1% penicillin/streptomycin antibiotics, 2 
mM L-glutamine and non-essential amino acids. They were maintained in 15 cm cell 
culture dishes in an incubator at 37°C with 5% CO2 and 95% humidity. Splitting was done 
twice per week when confluence reached approximately 80%. Therefore, cells were 
washed once with PBS and then detached by trypsin / EDTA treatment for approximately 3 
minutes. Trypsin was inactivated by addition of medium containing FCS and cells were 
seeded for passaging and experiments. In general cells were passaged 1:3 or 1:5 
depending on further usage after 3 or after 4 days. 
 
3.2.1.2 Isolation of immune cells from human blood 
Peripheral blood mononuclear cells (PBMCs) were isolated from blood of voluntary healthy 
donors (as approved by the local Ethic Committee Heidelberg, admission number:  
S-157/2006) by density gradient centrifugation. 15 ml Pancoll (density 1.077 g/ml) were 
pipetted in 50 ml Falcons tubes, blood was mixed with equal volume of PBS and carefully 
layered on top of the pancoll. After centrifugation at 1000 g for 20 min at 4°C without 
deceleration, the interphase (white ring of PBMCs) was collected and transferred into fresh 
50 ml Falcon tubes. Collected cells from two different Falcon tubes were pooled in one 
fresh Falcon tube, filled up to 50 ml with PBS and centrifuged at 365 g for 10 min at 4°C. 
Supernatant was discarded, cells were resuspended in 50 ml PBS and centrifuged at 300 
g for 15 min at 4°C. Again, supernatant was discarded and cells were now resuspended in 
10 ml PBS and pooled in one tube. PBS was added to a volume of 50 ml and the cell 
suspension was centrifuged at 365 g for 10 min at 4°C. Supernatant was discarded and 
cells were resuspended in 10 ml RPMI supplemented with 10% heat inactivated FCS. Cell 
titer was determined by counting cells in a Neubauer chamber after diluting the cells in 
Trypan blue. For some experiments CD14+ monocytes, CD56+ NK cells or CD304+ pDCs 
were purified or depleted by a positive selection kit according to the manufacturer’s 
instructions with an AutoMACS separator (magnetic activated cell sorting). After PBMC 
Materials & Methods 
34 
 
purification and counting a determined number of PBMCs was centrifuged at 300 g for 10 
min at 4°C. Cells were resuspended in the provided MACS assay buffer and microbeads 
with specific antibodies against the respective cell surface markers were added. Volumes 
of assay buffer and microbeads were used as instructed by the manufacturer dependent 
on the number of PBMCs used. After 15 min incubation at 4°C, 40 ml PBS was added and 
centrifuged at 300 g for 10 min at 4°C. Cells were resuspended in 2 ml PBS and 
separation was performed with the AutoMACS separator with the program suggested by 
the manufacturer. After purification, 10 ml medium was added to the cells and cells were 
centrifuged at 300 g for 10 min at 4°C. Subsequently, medium was removed, cells were 
resuspended in 0.5 - 2 ml of medium, counted and plated as indicated in the specific 
experiments. 
 
3.2.1.3 Generation of murine bone marrow derived macrophages (BMDM) and bone 
marrow derived dendritic cells (BMDC) 
Bone marrow cells were isolated from femora and tibiae of mice that were sacrificed by 
CO2 asphyxia. Bones were dissected and cut open at the ends. By using a 27 G needle 
and a 5 ml syringe bone marrow cells were flushed into a Falcon tube with the respective 
medium (see below). The cell suspension was centrifuged at 300 g for 7 min and the pellet 
was resuspended in 48 ml of medium. For differentiation into BMDM, 12 ml of bone 
marrow cells were seeded per 15-cm Petri dish in DMEM (10% FCS, and 1% 
penicillin/streptomycin) supplemented with 6 ml supernatant of L929 cells. Supernatant 
from L929 cells contains macrophage colony-stimulating factor (M-CSF) that leads to 
differentiation of bone marrow cells into macrophages112. At day 4 after seeding the same 
amount of L929 supernatant was added. After 7 days differentiated macrophages were 
harvested. Cells were washed with PBS and then scraped in DMEM supplemented with 
10% FCS. For generation of BMDCs, cells were seeded into 15-cm cell culture plates in 
RPMI 1640 supplemented with 4% LGM supernatant (containing GM-CSF), 10% FCS, 1% 
penicillin/streptomycin and 0.05 mM 2-ME. At day 4 fresh LGM supernatant was added 
and at day 7 non-adherent dendritic cells were harvested by centrifugation at 300 g for 10 
min. BMDC were then resuspended in RPMI supplemented with 10% FCS. 
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3.2.1.4 Co-culture setup 
For experiments where Huh cells were co-cultured with PBMCs, 1 x 105 Huh cells were 
seeded in 48-well plates in 200 µl DMEM. Following adherence of Huh cells 
(approximately 4 h) medium was removed and 1 x 106 PBMCs were added in 200 µl 
RPMI, as PBMCs did not survive in DMEM. After overnight co-culture supernatant or cells 
were harvested for further analysis. In experiments where purified subsets of specific 
immune cells were used for co-culture with Huh cells, 1 x 104 pDCs, 1 x 105 NK cells or 1 x 
105 monocytes were used. Accordingly, when these cells were depleted from PBMCs, 
those numbers were subtracted from 1 x 106 PBMCs. These numbers approximately 
resemble the number of each subset of innate immune cells in 1 x 106 PBMCs. 
In triple co-culture experiments 5 x 104 Huh-7 cells were seeded together with 5 x 104 Huh-
7 Con1 cells and 1 x 106 PBMCs.  
Co-culture experiments with murine cells were performed similarly. Here, 1 x 105 Hep56D 
cells were co-cultured with 3 x 105 BMDMs. 
 
3.2.1.5 Transwell setup 
Transwell inserts with a pore size of 1 μm were used to separate Huh-7 Con1 cells from 
PBMCs in the co-culture. For these experiments 1 x 105 Huh-7 Con1 cells and 1x106 
PBMCs were used in a 24-well plate with a total volume of 500 μl (350 μl bottom well, 150 
μl top well). Huh-7 Con1 cells were either seeded in the bottom or the top well in DMEM. 
After 4 h medium was removed and replaced by RPMI with 10% FCS. Along with that 
PBMCs were seeded in the opposite well also in RPMI with 10% FCS. For the setup of the 
invers transwell, the transwell inserts were placed in a sterile petri dish upside down. 
Thereby, Huh-7 Con1 cells were coated on the bottom of the transwell. After 4 h 
incubation medium was removed and transwell inserts were then placed into a 24 well 
plate and PBMCs were added in the top well. 22h after addition of PBMCs cell-free 
supernatants from both wells were collected and analyzed for IFNα levels by ELISA. 
 
3.2.1.6 CFSE and CytoRED staining of Huh cells 
In certain experiments Huh cells were labeled for flow cytometry analysis. Therefore, Huh 
cells were stained with CFSE or with CytotellTM RED (CytoRED) prior to seeding. A certain 
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amount of cells was centrifuged at 300 g for 7 min, resuspended in 1 ml PBS and 
incubated with the intracellular dye CFSE (4.5 μM in PBS) for 5 min at room temperature 
in the dark. Afterwards, cells were washed once with 10 ml PBS, once with 10 ml DMEM 
and then were seeded as described above. With exactly the same protocol Huh cells were 
stained with CytoRED for triple co-culture experiments. However, instead of staining cells 
with a 1x dye working solution of CytoRED as instructed by the manufacturer, cells were 
incubated with a 0.5x dye working solution to allow flow cytometry analysis (cells stained 
with 1x dye working solution were too bright). 
 
3.2.1.7 Infection of Huh-7.5 cells with HCV 
For HCV infection of Huh-7.5 cells the JC1 virus was used113. 5 x 104 Huh-7.5 cells were 
seeded in a 24-well plate in 500µl. After 24 h incubation, infection with the JC1 virus was 
performed for 6 h (MOI 3). Cells were then washed and stained with CFSE as described 
above inside the well. After 72 h, PBMCs were added to infected Huh-7 cells for overnight 
co-culture. Then cells were prepared for flow cytometry (see 3.2.2.3) and fixed with 1.5% 
PFA for 15 min at room temperature to allow further analysis under BSL1 conditions.  
 
3.2.1.8 Stimulation of cells with recombinant cytokines 
To analyze the effects of interferons on the uptake of Huh-7 cells by purified monocytes, 
these cells were co-cultured in the presence of 700 pg/ml IFNα or 7 ng/ml IFNγ. Equal 
amounts of IFNα were used in pre-stimulation experiments of either Huh-7 cells or purified 
monocytes. These amounts of cytokines were used as similar levels were measured in the 
co-culture of Huh-7 Con1 cells with PBMCs. 
Sensitivity of Huh-7 cells was analyzed by TRAIL and TNFα stimulation. Huh-7 cells were 
treated with 50 or 100 ng/ml of TRAIL or TNFα for different time points as indicated in the 
figure legends. 
 
3.2.1.9 Blocking antibodies 
In different sets of experiments blocking antibodies against CD81, CD9 or TRAIL and the 
appropriate IgG control antibodies were used. In these experiments, co-cultures were set 
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up as described before (see 3.2.1.4). Antibodies were added to PBMCs directly before 
addition of PBMCs to Huh-7 cells. The concentrations used are given in the respective 
figure legends. 
Experiments were performed to analyze the effect of IFNα on viral replication. Therefore, 
conditioned supernatant from the co-culture of HCV SGR cells with PBMCs was 
harvested. The conditioned supernatant was treated with an IFNα blocking antibody or an 
appropriate IgG control antibody for 1h in different dilutions and was then added to Huh-7 
Luc JFH cells. Stock concentrations of both antibodies were 0.5 mg/ml. Dilutions used are 
given in the respective figure legends. 
 
3.2.1.10 Exosome purification 
Exosomes were isolated from supernatants of Huh-7 cells by subsequent centrifugation steps. 
Supernatants from 6 15 cm cell culture plates were pooled after 3 days of seeding. First, the 
supernatant was centrifuged at 300 g for 10 min at 4° C to remove cell debris. The pellet was 
discarded, and the supernatant again cleared by centrifugation at 2000 g for 20 min at 4°C 
followed by centrifugation at 10,000 g for 30 min at 4°C. The cleared supernatant was then 
used for ultracentrifugation at 100,000 g (28,000 rpm with a SW28 rotor) for 4 hours at 4° C. 
The supernatant was then discarded and the pellet containing exosomes was resuspended in 
PBS. 
 
3.2.2  Immunoassays 
3.2.2.1 Enzyme-linked immunosorbent assay (ELISA) 
Cytokine secretion was quantified by Sandwich-ELISA. Cell-free supernatants were 
harvested and cytokine levels were measured according to the manufacturer’s 
instructions. However, ELISAs were performed in half area plates. Accordingly, the 
volumes were adjusted to this setup. For detection of IFNα and murine IL-6 pure samples 
were used, while for IFNγ samples were diluted from 1:2 to 1:10 in ELISA blocking buffer. 
Samples that were stimulated by R848, CpG-DNA or LPS were diluted 1:10. 
Measurements were performed with the Sunrise plate reader and standard curves were 
plotted by the software Tecan Magellan. 
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3.2.2.2 LuminexTM assay  
Next to cytokine quantification by ELISA, in cooperation with Prof. Dr. Christine Falk 
(Hannover) a LuminexTM assay was performed. Luminex™ allows the detection of multiple 
cytokines simultaneously within the same sample. Therefore, beads coated with different 
cytokine-specific antibodies are used. Moreover, beads are color-coded which allows an 
assignment of each bead to a specific cytokine. Beads are incubated with the sample and 
captured cytokines are then detected by biotinylated detection antibodies. A PE- 
streptavidin-conjugate is added to the samples and the beads are then analyzed by a dual 
laser instrument. While one laser is used for differentiation of the beads based on their 
color code, the other laser measures the PE signal which correlates with the amount of 
cytokine in the sample. A standard curve for each cytokine allows quantification. 
For Luminex analysis undiluted supernatants of 4 independent experiments were sent to 
Prof. Dr. Christine Falk. Supernatants were collected from Huh-7 cells, PBMCs, Huh-7 
Con1 cells and Huh-7 JFH cells cultured alone and from the co-culture of Huh-7 cells with 
PBMCs, of Huh-7 Con1 cells with PBMCs and of Huh-7 JFH cells with PBMCs. Cell 
numbers and volumes were used as described in 3.2.1.4. Also Huh-7 cells cultured alone 
were kept in RPMI from the time point on where co-cultures were set up. 
 
3.2.2.3 Flow cytometry  
To check for purity of purified immune cells (or for depletion efficiency) 2x105 isolated cells 
were pipetted into FACS-tubes and mixed with 500 μl of FACS buffer. Samples were then 
centrifuged at 300 g for 5 min at 4°C and supernatant was discarded afterwards. Cells 
were resuspended in 100 μl FACS buffer, antibodies were added (in the dilution suggested 
by the manufacturer) and shortly vortexed. As negative controls samples were included 
without addition of the antibody. After 15 min at 4°C in the dark, 1 ml FACS buffer was 
added, shortly vortexed and centrifuged as before. Supernatant was discarded and cells 
were resuspended in 300 μl FACS buffer. FACS analysis was performed with a BD FACS 
Canto. If necessary, compensation was performed using single stains with the BD DivaTM 
software. 
In experiments where Huh-7 cells and PBMCs (or purified monocytes) were co-cultured, 
cells were harvested for flow cytometry by the following procedure. Supernatants 
containing suspension cells were transferred to FACS tubes. Adherent cells were washed 
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with PBS, Trypsin/EDTA was added and incubated for 3 min at 37°C. Cells were 
resuspended carefully to obtain single cells and transferred to the same FACS tubes as 
the supernatant before. 
For intracellular staining of IL-8, co-cultures of Huh-7 cells and PBMCs were set up as 
described. To mark Huh-7 cells, they were stained with CFSE prior to seeding. Brefeldin A 
(1 μg/ml) was added 14 h after PBMC addition to block cytokine secretion. After additional 
6 h, cells were harvested as described before and washed with FACS buffer (centrifuged 
at 365 g for 5 min at 4°C). Monocytes were stained with CD14-PE as described above. 
After another wash, cells were fixed by addition of 250 μl 1.5% PFA under mild vortexing. 
Samples were incubated for 15 min at room temperature and washed twice with FACS 
buffer. Pellets were re-suspended in 500 μl permeabilization buffer and incubated for 5 min 
at 4°C. Cells were centrifuged, resuspended in 100 μl permeabilization buffers and 
incubated with anti-IL-8-APC antibody for 20 min at 4°C in the dark. Afterwards, cells were 
washed, resuspended in 300 μl FACS buffer and analyzed with the BD FACS Canto. 
Unstained controls as well as Huh-7 cells and Huh-7 Con1 cells seeded alone were used 
to determine background fluorescence. 
In order to investigate uptake by monocytes, CFSE (or CytoRED) labeled Huh cells were 
co-cultured with PBMCs or purified monocytes as described. After harvesting (see above), 
cells were washed with FACS buffer and centrifuged at 365 g for 5 min at 4°C. Cells were 
resuspended in 100 μl FACS buffer and stained with CD14-PE as described. Cells were 
washed, resuspended in 300 μl FACS buffer and analyzed with the BD FACS Canto. 
CFSE signal was detected in the FITC channel, CytoRED in the APC channel. Single 
stains were used for compensation of the overlapping emission spectrum for CFSE and 
the PE channel.  
Detection of the activation markers CD80 and CD86 on monocytes was performed by 
staining monocytes with CD14-APC and with CD80-PE or CD86-PE antibodies. NK cells 
activation markers CD69 and CD25 as well as TRAIL were analyzed on NK cells (CD56+ 
and CD3-) by the following stainings:  
CD25-PerCP-Cy5.5, CD56-APC and CD3-FITC. 
CD69-APC, CD56-Pe-Cy7 and CD3-FITC  
TRAIL-PE, CD56-APC and CD3-APC-Cy7 
Materials & Methods 
40 
 
3.2.2.4 ImageStream analysis 
ImageStream technology is a combination of flow cytometry and microscopy. A picture is 
taken of every cell that runs through the flow chamber, thereby giving detailed information 
about the localization of staining detected by flow cytometry. For ImageStream analysis 
CFSE-stained Huh-7 cells were co-cultured with PBMCs overnight. Cells were harvested 
in the same procedure as described before for flow cytometry. After staining with CD14-
PE, cells were fixed by addition of 250 μl 1.5% PFA under mild vortexing. Samples were 
incubated for 15 min at room temperature and washed twice with FACS buffer. Pellets 
were re-suspended in 500 μl permeabilization buffer and incubated for 5 min at 4°C. Cells 
were washed and then stained with Hoechst (1:10000) for 15 min at 4°C to stain nuclei. 
After another wash cells were resuspended in PBS and subjected to ImageStream 
analysis by PD Dr. Guido Wabnitz (Heidelberg). Measurements were recorded using an 
IS100 ImageStream device and analyzed with the software IDEAS version 6.0. For 
detection of the uptake of Huh-7 cells by monocytes, gates were set to detect CD14+ 
monocytes that were also positive for CFSE. Microscopy pictures of these cells were then 
depicted. 
 
3.2.3  Molecular Biology 
3.2.3.1 Quantitative real time PCR (qPCR) 
To quantify the amount of viral RNA qPCR was performed. RNA from Huh cells and from 
the supernatant of the cells was isolated with the NucleoSpin® RNA kit according to the 
protocol. In addition, RNA lysis buffer was spiked with an in-vitro transcript of Firefly 
Luciferase 2 (FL2). Thereby, a defined amount of RNA is present in each sample, which 
allows a normalization of viral RNA levels. Especially for quantification of viral RNA in the 
supernatant this is necessary, as RNA of standard housekeeping genes is not present in 
the supernatant. cDNA was synthesized using the High Capacity cDNA Reverse 
Transcription Kit according to manufacturer’s instructions. As a negative control one 
sample was pipetted without reverse transcriptase (noRT). qPCR was then conducted with 
the SYBR Green Master Mix, which was mixed with water, cDNA (1:4 diluted before) and 
HCV specific primers to a final volume of 20 μl in a Micro Amp Fast 96-well Reaction plate 
(0.1ml). Water and noRT samples served as negative controls. The plate was covered with 
an Optical Adhesive Cover, centrifuged shortly and subjected to analysis in the Real Time 
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PCR System Step-One-Plus (Program setup: 95 °C 15 min; 40x [95°C 3 sec; 55°C 1 min, 
60°C 1min]). Relative expression of viral RNA was calculated by the ΔCT compared to the 
FL2 expression (rE = 2^(- ΔCT)). 
Expression levels of cellular mRNA were quantified in a similar way. However, RNA was 
isolated with the PeqGold Total RNA Kit and expression was normalized to the 
housekeeping gene β-actin. 
 
3.2.3.2 Small interfering RNA (siRNA) transfection 
4 x 104 Huh cells were seeded per well in a 24-well plate. After overnight incubation, 6 
pmol of siRNA were mixed with 1 μl of Lipofectamine RNAiMAX transfection reagent in 
100 μl of OptiMEM and incubated for 5 minutes at room temperature. This mix was added 
to cells dropwise. Medium was exchanged 24 h after transfection together with addition of 
PBMCs. siRNA targeting GFP (which was not expressed in Huh-7 cells) was used as 
control. 
 
3.2.3.3 Surface proteome analysis 
In order to compare the surface proteins between Huh-7 and Huh-7 Con1 cells, the 
surface proteome of both cells was analyzed by mass spectrometry. To extract surface 
proteins the Pierce Cell Surface Protein Isolation Kit was used according to the 
manufacturer’s instructions. In brief, surface proteins were labeled by EZ-Link™ Sulfo-
NHS-SS-Biotin (a thiol-cleavable amine-reactive biotinylation reagent). Cells were lysed 
and biotinylated surface proteins were purified with NeutrAvidin Agarose. After several 
washing steps, 400µl SDS page sample buffer containing DTT was added to break the 
disulfide bonds which led to elution of the proteins. Eluted proteins were then subjected to 
mass spectrometry analysis which was performed by Dr. Robert Hardt in the core facility of 
the ZMBH Heidelberg. Proteins were separated by SDS-PAGE and stained with 
Coomassie Brilliant Blue R-250. Gels were cut in 8 fractions, proteins were digested by 
trypsin treatment and analyzed by mass spectrometry (Q-Exactive HF MS). Analysis was 
performed by Perseus software. 
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3.2.4  Biochemistry 
3.2.4.1 Western Blot 
To harvest samples for Western Blotting, cells were washed once with PBS, lysed in 1x 
SDS PAGE sample buffer and incubated at 95°C for 10 min. Samples were loaded onto a 
10% acrylamide gel and run in a vertical gel chamber at 80 V for approximately 2 hours. 
Separated proteins were transferred to a nitrocellulose membrane by semidry blotting at 
1.75 mA/cm2 for 1 hour and 15 minutes. After blotting Ponceau S was used to control for 
an efficient transfer of the proteins. Unspecific binding was then blocked by incubating the 
membranes in 5% dry milk in 1xTBST for 1 h at room temperature. Primary antibodies 
against cleaved PARP and ß-actin were diluted in blocking buffer 1:1000 and 1:5000, 
respectively. Membranes were incubated with primary antibody overnight at 4°C, washed 
three times for 10 min with 1xTBST at RT and incubated with HRP-conjugated anti rabbit 
antibody diluted 1:4000 in blocking buffer for 45 min at RT. Again, membranes were 
washed as described above and proteins were then detected by using enhanced 
chemiluminescence (ECL) substrate (1:1 mix of Reagent A and Reagent B added to the 
membrane). Densitometric analysis was performed using ImageJ software. 
 
3.2.4.2 Luciferase assay 
Huh-7 Luc JFH cells were seeded in 96-well plates as described above. After 4h, DMEM 
was removed and cells were incubated overnight with 200 µl conditioned supernatant 
(derived from co-culture of Huh-7 Con1 cells with PBMCs). Medium was removed and 
cells were lysed in 50 μl Luciferase lysis buffer. Plates were placed on a shaker for 15 min 
at RT and subsequently frozen at -80°C. After complete freezing, cells were thawed at RT 
and samples were analyzed with a plate luminometer. 300 μl of Luciferase assay buffer 
were injected into each well automatically, and light signal was measured for 10 seconds. 
40 μl of a 10% SDS solution were injected to stop the light reaction. Luciferase activity in 
Huh-7 Luc JFH cells kept in fresh medium was used as a reference. The luciferase activity 
measured in these cells was set to 100%. Supernatants from PBMCS or from Huh-7 Con1 
cells alone served as additional controls. 
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3.2.4.3 Lactate dehydrogenase (LDH) release assay 
Release of LDH was used to quantitatively measure cytotoxicity using the Cytotoxicity 
Detection Kit Plus (LDH). Typically, LDH is an intracellular protein, but is released from 
cells during apoptosis or necrosis. Upon release of LDH, activity of the enzyme can be 
detected in the supernatant. Addition of an LDH substrate results in its conversion into a 
red-colored product causing colorimetric shift of cell culture supernatants, which is 
proportional to LDH content and cytotoxicity and can be measured by a photometer. 
Measurement of extracellular LDH activity was determined according to the manufacturer’s 
protocol, however, with half the volumes suggested. Huh cells were incubated with 
recombinant proteins or with PBMCs overnight. As a positive control (100% killed cells) 1 
μl Tween-20 was added to Huh cells, carefully mixed and incubated for 30 min at 37°C. To 
determine background activity, each population of cells used in a specific experiment was 
cultured alone in an extra well. Cell culture supernatants were harvested in tubes and 
centrifuged at 300 g for 10 min at 4°C. 50 μl of cell-free supernatants were transferred to 
96-well F-bottom plates and incubated with 50 μl of the reaction mixture for 30 min in the 
dark. Reaction was stopped by addition of 25 μl of the provided stop solution. Absorbance 
was read with the Sunrise ELISA reader at 490 nm. 
To determine the percentage of killed Huh cells, culture medium background was 
subtracted from all values. Subsequently, the formula provided in the instructions was 
used to calculate the percentage of cytotoxicity in Huh cells: In detail, spontaneous cell 
death of target cells (Huh cells) and effector cells (e.g. PBMCs) were subtracted from 
experimental values of the co-culture, followed by normalization to maximum release from 
target cells (Huh cells lysed by Tween-20) subtracted by spontaneous cell death of target 
cells. This quotient was multiplied with 100 to obtain the percentage of cytotoxicity. All 
samples were set up as duplicates. 
             ( )   
(         )           
     (     )      
      
 
3.2.5  Statistical analysis 
All experiments were performed at least three times unless indicated otherwise in the figure 
legends. Error bars indicate the standard deviation (SD). For all experiments in which PBMCs 
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from different donors were used, it was analyzed by ANOVA whether the donor differences 
had a significant effect. In that case a linear mixed effect model was performed to add a 
random effect due to the donor variations. Thus, distribution of samples had no implications, 
as linear mixed effect models are robust against breaking the normality assumption. Finally, 
multiple comparisons were performed by Anova followed by a Tukey post-hoc test to analyze 
significant differences in different conditions. p<0.05 (*), p<0.01 (**) and p<0.001 (***) were 
considered significant. Non-significant differences were indicated by ns. All calculations were 
performed with R. 
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4 Results 
4.1 pDC activation by Hepatitis C virus subgenomic replicon cells 
depends on viral RNA and cell-cell contacts 
4.1.1 pDCs secrete IFNα in response to Hepatitis C virus subgenomic replicon cells 
In order to analyze the response of innate immune cells against the Hepatitis C virus, at 
first an experimental approach had to be established. Previous studies had shown that the 
co-culture of Hepatitis C virus subgenomic replicon (HCV SGR) cells and human 
peripheral blood mononuclear cells (PBMCs) resulted in IFNα secretion by plasmacytoid 
dendritic cells (pDCs)59. Thus, a co-culture system was used here to further analyze the 
innate immune response against HCV. To establish the experimental setup IFNα secretion 
by PBMCs in co-culture with HCV SGR cells was analyzed. In preliminary experiments 
various parameters were tested. The time point of addition of PBMCs to HCV SGR cells as 
well as the number of SGR cells and PBMCs were optimized (data not shown) to obtain a 
reliable and reproducible activation of PBMCs. Of note, as this project focused on the role 
of viral RNA in PBMC activation, HCV SGR cells were used instead of HCV infected cells. 
 
In this study the HCV SGR cell termed Huh-7 Con1 (HCV genotype 1b) was used. Naïve 
Huh-7 hepatoma cells as well as Huh-7 Con1 cells that were cured from the replicon 
(“cured Con1”) served as controls for specific PBMC activation by HCV SGR cells. Indeed, 
IFNα was secreted in the co-culture of the HCV SGR cell line Huh-7 Con1 with PBMCs 
(Fig. 4-1 A). Neither Huh-7 nor cured Con-1 cells triggered IFNα production by PBMCs. To 
confirm that pDCs within the PBMC fraction produced IFNα, pDCs were depleted from 
PBMCs before addition to Huh-7 Con1 cells. After pDC depletion no IFNα was detected 
anymore (Fig. 4-1 B). In another approach purified pDCs were co-cultured with Huh-7 
Con1 cells. Similar to complete PBMCs, in this setup IFNα was secreted (Fig. 4-1 C) 
proving that pDCs respond to HCV SGR cells with secretion of IFNα. 
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Fig. 4-1 pDCs secrete IFNα in response to Hepatitis C virus subgenomic replicon cells 
(A) Huh-7 cells (Huh-7 has no HCV SGR, Huh-7 Con1 carries HCV SGR genotype 1b, cured Con1 were 
cured from the replicon by IFN treatment) were co-cultured with PBMCs overnight. Supernatants were 
collected and measured for IFNα secretion by ELISA. (B) IFNα levels in co-cultures with PBMCs or with 
PBMCs depleted from pDCs (PBMC -pDC). (C) IFNα levels in co-cultures with MACS-purified pDCs (n=3). 
 
4.1.2 Secreted IFNα inhibits viral replication 
Having observed that pDCs secreted IFNα in co-culture with HCV SGR cells, the question 
was addressed whether the amount of type I IFN was sufficient to exert an anti-viral effect. 
To analyze this, Huh-7 JFH (HCV genotype 2a) SGR cells that additionally encode a 
luciferase gene were used (Huh-7 Luc JFH). With these Huh-7 Luc JFH reporter cells viral 
replication can be measured in a Luciferase assay. Inhibition of replication reduces the 
amount of luciferase and thereby the luciferase activity is decreased. 
Huh-7 Luc JFH reporter cells were incubated overnight with conditioned supernatant 
derived from the co-culture of Huh-7 Con1 cells and PBMCs. Conditioned supernatant 
significantly reduced the luciferase activity in a dose-dependent manner (Fig. 4-2 A). 
Remarkably, the anti-viral effect of the conditioned supernatant was even observed at high 
dilutions. For example a 1:500 dilution reduced luciferase activity by 94.7%. The calculated 
IC50 dilution was at 1:2231. According to ELISA data the conditioned supernatant 
comprised 330 pg/ml of IFNα, indicating that 0.15 pg/ml IFNα inhibited viral replication by 
50% (assuming the effect is mostly caused by IFNα, but also other cytokines might also 
inhibit viral replication). 1:2 diluted supernatant from Huh-7 Con1 cells or PBMCs cultured 
alone had no influence on the luciferase activity. Noteworthy, as no IFNα could be 
detected in a 1:500 dilution by ELISA, the Luciferase assay served as a bioassay with 
higher sensitivity. 
To confirm that the observed reduction in viral replication was caused by IFNα, 
experiments using IFNα blocking antibodies were done in which the conditioned 
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supernatant was incubated with the antibody prior to addition to Huh-7 Luc JFH reporter 
cells. Indeed, blocking IFNα significantly restored Luciferase activity compared to 
conditioned supernatant with IgG control antibodies at the respective concentrations (Fig. 
4-2 B). With the highest concentration of IFNα blocking antibody luciferase activity was 
restored to 58% (medium control set to 100%). Thus, IFNα blocking was either not 
complete or not only IFNα but also other secreted cytokines by PBMCs affected viral 
replication. Nevertheless, the results clearly showed that activation of PBMCs in the co-
culture with HCV SGR cells leads to secretion of bioactive IFNα, which in turn inhibits viral 
replication. 
 
 
Fig. 4-2 pDC secreted IFNα inhibits viral replication 
(A) Huh-7 Luc JFH cells were incubated overnight with different dilutions of conditioned 
supernatant (SN) from the co-culture of Huh-7 Con1 cells and PBMCs. Supernatants from Huh-7 
Con1 cells and PBMCs alone were used as controls. After overnight incubation, supernatant was 
removed, cells were lysed in luciferase lysis buffer and luciferase activity was measured. 
Significance is indicated compared to RPMI control (n=3). 
(B) Conditioned supernatant (SN) from the co-culture of Huh-7 Con1 cells and PBMCs was diluted 
1:500 and pretreated with an IFNα or an IgG control antibody in the same concentrations for 1 h. 
Huh-7 Luc JFH cells were then incubated with these pretreated supernatants overnight. After 
overnight incubation experiments were conducted as in (A) Significance is indicated compared to 
IgG control antibodies (n=3). 
 
4.1.3 pDCs are stimulated by viral RNA in co-culture with HCV SGR cells 
Previous experiments showed that pDCs were activated in the co-culture with Huh-7 Con1 
cells and that they secreted IFNα, which exerted an anti-viral activity. However, it was 
unclear what exactly the stimulus for pDC activation is. As a previous study provided 
evidence that viral RNA triggers pDC activation59, this hypothesis was further investigated. 
Several SGR cells (Huh-7 JFH, Huh-7 Con1, Huh-7 Con1 mutants K1846T, S2204R and 
E1202G+T1280S+K1846T, Huh-6 Con1) were therefore tested: the different mutations in 
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the Con1 background influence the replication efficiency of the replicons (V. Lohmann, 
Dpt. of Molecular Virology, personal communication). Hence, pDCs would encounter 
different amounts of viral RNA in the co-culture. If viral RNA in fact is the stimulus for pDC 
activation, the difference in viral RNA levels should result in a different degree of pDC 
activation.  
To analyze this, co-cultures of the various SGR cells with PBMCs were performed. pDC 
activation was measured by IFNα secretion and viral RNA was quantified in the 
supernatant of SGR cells. In three independent experiments a positive correlation between 
viral RNA in the supernatant and IFNα production by pDCs was observed (Fig. 4-3). For 
Huh-7 JFH and the Huh-7 Con1 E1202G+T1280S+K1846T mutant SGR cell only low 
amounts of viral RNA were detected in the supernatants. Accordingly, no or very low levels 
of IFNα were measured in the co-cultures with PBMCs. In contrast, supernatants of Huh-7 
Con1 SGR cells showed high amounts of viral RNA. In consequence, high levels of IFNα 
were produced by pDCs in the co-culture. The other tested SGR cells showed 
intermediate RNA levels and in line with that intermediate IFNα production by pDCs. 
 
 
Fig. 4-3 IFNα secretion by pDCs correlates with secreted levels of viral RNA 
Different SGR cells (Huh-7 JFH, Huh-7 Con1, Huh-7 Con1 mutants K1846T, S2204R and 
E1202G+T1280S+K1846T, Huh-6 Con1) were co-cultured with PBMCs overnight. Supernatants were 
collected and measured for IFNα level by ELISA. In parallel, only SGR cells were seeded for quantification of 
viral RNA in the supernatant by qPCR. RNA lysis buffer was spiked with a Firefly Luciferase 2 (FL2) in vitro 
transcript for normalization. Three independent experiments are shown (A, B and C). r = Pearson correlation 
coefficient. 
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4.1.4 Bafilomycin inhibits pDC activation in co-culture with HCV SGR cells 
The observation that secretion of viral RNA from HCV SGR cells correlated with IFNα 
production by pDCs already indicated that viral RNA might be triggering pDC activation. 
Expression of the endosomal nucleic acid pattern recognition receptor TLR7 in pDCs 
allows recognition of viral RNA. The role of viral RNA in pDC activation was further 
investigated using Bafilomycin and Chloroquine which both inhibit endosomal acidification. 
Thereby, endosomal TLRs lose their function and TLR mediated nucleic acid recognition is 
inhibited114,115, while cytosolic RNA sensors are known to be insensitive to Bafilomycin. 
Addition of Bafilomycin resulted in complete inhibition of pDC activation in the co-culture of 
Huh-7 Con1 cells and PBMCs (Fig. 4-4 A). To control specificity of the drug, PBMCs were 
also stimulated with LPS (TLR4 agonist, not endosomal) in the presence of Bafilomycin. 
Since TLR4 signaling does not result in IFNα secretion, IL-6 secretion was used as 
readout. LPS stimulation of PBMCs was not influenced by Bafilomycin (Fig. 4-4 B). The 
effects observed with Bafilomycin were reproduced with Chloroquine. Chloroquine 
prevented pDC stimulation in co-culture with Huh-7 Con1 cells (Fig. 4-4 C), but had no 
impact on LPS stimulation (Fig. 4-4 D). Hence, pDC stimulation by Huh-7 Con1 cells was 
dependent on endosomal signaling, probably mediated by TLRs. 
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Fig. 4-4 Inhibition of endosomal TLRs affects pDC stimulation in co-culture with HCV SGR cells 
(A, C) Huh-7 Con1 cells were co-cultured overnight with PBMCs that were pre-incubated with indicated 
concentrations of Bafilomycin (Bafi) or Chloroquine (Cq) for 1 h. Drugs were also present during co-culture 
period (n=3). (B, D) PBMCs were stimulated with LPS (0.1 ng/ml) under drug treatment (n=3). After overnight 
co-culture, supernatants were collected and measured for IFNα and IL-6 secretion by ELISA. 
 
4.1.5 Response of murine bone marrow derived macrophages (BMDM) in co-culture 
with HCV SGR cells is partly dependent on TLR7 and fully dependent on 
endosomal TLR signaling 
Experiments with human PBMCs revealed that endosomal recognition of viral RNA 
triggers pDC activation. To further investigate which TLRs contribute to the recognition of 
viral RNA, the co-culture setup was established in a murine system. This allowed the use 
of immune cells with defined deficiency for certain Toll-like receptors. The murine SGR 
cells Hep56D JFH were co-cultured with bone marrow derived macrophages (BMDM) and 
with bone marrow derived dendritic cells (BMDC) from wildtype mice. Interestingly, only 
BMDM, but not BMDC responded with IL-6 production in the co-culture with SGR cells 
(data not shown). 
To analyze if recognition of viral RNA plays a role in the response of BMDM in the co-
culture with SGR cells, BMDM from TLR7 KO mice were used, as TLR7 is known to 
recognize single stranded RNA. When comparing the stimulation of wildtype BMDM and 
TLR7 KO BMDM in the co-culture, it was observed that the production of IL-6 by TLR7 KO 
BMDM was significantly decreased (Fig. 4-5 A). TLR7 KO BMDM responded to the 
positive controls CpG-DNA (TLR9) and LPS (TLR4) in the same range as wildtype BMDM. 
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However, they did not respond to the TLR7 agonist R848, which proved that activation via 
TLR7 in these cells was not functional. 
Although IL-6 levels were significantly lower in TLR7 KO BMDM, IL-6 was still detectable. 
Hence, in the next experiments mutant Unc93b1 mice were used. Unc93b1 is essential for 
trafficking of endosomal TLRs from the ER to endosomes37. Accordingly, in mutant 
Unc93b1 mice all endosomal TLRs are not functional and recognition of nucleic acids is 
prevented. Indeed, BMDM from mutant Unc93b1 mice were not stimulated at all by SGR 
cells, while wildtype BMDM produced IL-6 (Fig. 4-5 B). Upon LPS stimulation, which is 
recognized by TLR4 (not endosomal) mutant Unc93b1 BMDM and wildtype BMDM 
responded equally. In summary these results clearly showed that viral RNA is recognized 
by TLR7 with other endosomal TLRs also contributing. Thus, the experimental data 
support the previous finding of TLR mediated viral RNA recognition by human PBMCs. 
 
 
Fig. 4-5 Stimulation of BMDM in co-culture with murine HCV SGR cells is reduced in TLR7 KO mice 
and lost in mutant Unc93b1 mice 
The murine HCV SGR cell Hep56D JFH was co-cultured with bone marrow derived macrophages (BMDM) 
from wildtype and TLR7 KO mice (A) or BMDM from mutant Unc93b1 mice (B) overnight. Supernatants were 
collected and measured for IL-6 levels by ELISA. R848 (1 μg/ml), CpG (1μM) and LPS (0.1 ng/ml) were used 
as positive controls (n=2). 
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4.1.6 Inhibition of exosome release reduces IFNα secretion 
Having shown that viral RNA is stimulating pDCs, the next open question was how viral 
RNA is transported from HCV SGR cells into specialized immune cells that recognize the 
viral RNA as a PAMP and elicit an immune response. It has been published that viral RNA 
is secreted via exosomes and thereby transported to pDCs63. Thus, it was analyzed 
whether exosomes play a role in the stimulation of pDCs in co-culture with Huh-7 Con1 
cells. Therefore, GW4869 and Spiroepoxide were used as exosome release inhibitors. 
Both inhibitors act via inhibition of neutral sphingomyelinases116 but are structurally 
unrelated. If viral RNA in fact is transported via exosomes, an inhibition of exosome 
release would decrease the amount of secreted viral RNA. In turn, this should attenuate 
PBMC stimulation. 
Thus, Huh-7 Con1 cells were treated with GW4869 or Spiroepoxide directly after seeding 
and over the entire period of co-culture with PBMCs. GW4869 significantly reduced the 
production of IFNα in co-culture with Huh-7 Con1 cells (Fig. 4-6 A). DMSO and GW4869 
had no influence on R848 stimulation of PBMCs (Fig. 4-6 B), indicating that viability of 
pDCs was not affected by GW4869. However, the results obtained with GW4869 were not 
reproducible with Spiroepoxide: Spiroepoxide did not affect PBMC stimulation in co-culture 
with Huh-7 Con1 cells (Fig. 4-6 C). 
Due to the inconsistent results with the two different exosome release inhibitors, in a third 
approach Rab27a was knocked down by siRNA. Rab27a is known to contribute to 
exosome release117. Knockdown of Rab27a significantly reduced IFNα secretion, but IFNα 
was still detectable in considerable amounts (Fig. 4-6 D), although the knockdown reduced 
Rab27a mRNA levels 83x fold (Fig. 4-6 E). In summary, exosome release inhibition 
experiments gave no clear answer, in how far viral RNA is transported to pDCs via 
exosomes. 
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Fig. 4-6 pDC activation by HCV SGR cells is partly influenced by exosome release inhibition 
Huh-7 Con1 cells were seeded in the presence of the exosome release inhibitors GW4869 (GW, 15 μM, (A) 
and (B)) or Spiroepoxide (SPIR, 5 μM, (C)). PBMCs were added 4 h after seeding and inhibitors were 
included also during co-culture. PBMCs stimulated with R848 (1 μg/ml) in the presence of inhibitors and 
DMSO were used as controls (B and C). (D) Huh-7 Con1 cells were treated with siRNA against Rab27a 
before addition of PBMCs. After overnight co-culture, supernatants were collected and measured for IFNα 
levels by ELISA. (E) qPCR analysis of Rab27a knockdown efficiency. n=5 for (A), n=2 for (B), n=4 for (C), 
n=3 for (D), n=1 for (E). 
 
4.1.7 Purified exosomes from HCV SGR cells do not activate pDCs 
In another approach to investigate the role of exosomes in transmission of viral RNA, 
exosomes were purified from HCV SGR cells and incubated with PBMCs. However, 
exosomes from Huh-7 Con1 cells did not cause IFNα secretion by pDCs (Fig. 4-7 A). Also 
the hypothesis that additional cell contacts of PBMCs to naïve Huh-7 or Huh-7 JFH cells 
(which by themselves did not significantly activate pDCs (Fig. 4-3)) together with 
exosomes from Huh-7 Con1 cells could cause stimulation of pDCs was proven wrong (Fig. 
4-7 A). In numerous experiments purified exosomes did not trigger IFNα secretion. This 
was even more surprising when the amount of RNA was quantified. PBMCs cultured with 
purified exosomes from Huh-7 Con1 cells were exposed to 144x more viral RNA 
compared to the level of viral RNA in the supernatant of the direct co-culture with Huh-7 
Con1 cells (Fig. 4-7 B). This led to the conclusion that purified exosomes are not sufficient 
to stimulate pDCs and that an alternative transport mechanism between HCV SGR cells 
and pDCs must exist. 
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Fig. 4-7 Purified exosomes from HCV SGR cells do not activate pDCs 
(A) Exosomes were purified from Huh-7 or Huh-7 Con1 cells and co-cultured with PBMCs alone or with 
PBMC together with Huh-7 or Huh-7 JFH cells overnight. Supernatants were collected and measured for 
IFNα secretion by ELISA (n=2). (B) Viral RNA content was determined by qPCR in purified exosomes and in 
the supernatant of Huh-7 Con1 cells (n=1). 
 
4.1.8 Direct cell-cell contact between HCV SGR cells and pDCs is required for pDC 
activation 
As purified exosomes did not stimulate pDCs, it was hypothesized that a direct contact 
between pDCs and HCV SGR cells is needed for transfer of viral RNA and subsequent 
pDC activation. To prevent direct cell-cell contact, PBMCs were separated from Huh-7 
Con1 cells by a transwell (1µM pore size, which should allow diffusion of exosomes) in 
different setups resulting in physical separation with different distances. Independent of the 
position of PBMCs and Huh-7 Con1 cells no IFNα was secreted in transwell experiments 
(Fig. 4-8 A). In a second approach formation of cell-cell contacts was disturbed 
mechanically. Therefore, co-cultures were set up in parallel in two different plates. One of 
these plates was placed on an orbital shaker, while the other one was incubated without 
any movements. Afterwards pDC activation was analyzed by measuring IFNα in both 
conditions. PBMCs were also stimulated by R848 to control that shaking had no effect on 
PBMC viability and uptake of stimulating agents. In the co-culture of PBMCs with Huh-7 
Con1 cells IFNα secretion was reduced by 83.4% when shaking (Fig. 4-8 B). R848 
stimulation was not affected by shaking. These results indicated that tight cellular contacts 
between PBMCs and Huh-7 Con1 cells promote an efficient activation of pDCs. 
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Fig. 4-8 Direct cell-cell contacts between HCV SGR cells and pDCs are required for pDC activation 
(A) Huh-7 Con1 cells (depicted in green) were directly co-cultured with PBMCs (depicted in red) or separated 
by transwell (1µm pore size, membrane thickness 10 µm) as indicated. After overnight incubation, 
supernatants were collected and measured for IFNα secretion by ELISA (n=3). (B) Huh-7 Con1 cells were 
co-cultured with PBMCs either with or without mechanical agitation (orbital shaker, 200 rpm). After overnight 
co-culture, supernatants were collected and measured for IFNα levels by ELISA (n=4). 
 
4.1.9 The tetraspanins CD81 and CD9 are involved in cell-cell contacts between 
HCV SGR cells and pDCs 
Since previous experiments revealed a critical role of cell-cell contacts for pDC activation, 
in the next part it was analyzed how HCV SGR cells and pDCs interact with each other. An 
earlier study suggested a role of CD81 and CD9 in this interaction118. In consequence, it 
was analyzed if these surface proteins also played a role in the co-culture setup by using 
specific blocking antibodies. Indeed, blocking CD81 by antibodies significantly reduced 
IFNα secretion compared to IgG control antibodies. Similar results were observed when 
CD9 was blocked (Fig. 4-9). However, neither blocking of CD81 nor of CD9 completely 
prevented IFNα production, indicating that further interactions between HCV SGR cells 
and pDCs occur. 
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Fig. 4-9 CD81 and CD9 are involved in cell-cell contacts between HCV SGR cells and pDCs 
Huh-7 Con1 cells were co-cultured with PBMCs in presence of CD81 (A, 0.1, 1, 2.5 µg/ml) or CD9 (B, 0.1, 1 
µg/ml) blocking antibodies and respective IgG control antibodies. PBMCs stimulated with R848 (1 µg/ml) 
were incubated with the highest concentration of each antibody. After overnight co-culture, supernatants 
were collected and measured for IFNα levels by ELISA (n=4) 
 
In summary, in this first part it was shown that pDCs respond to HCV SGR cells by IFNα 
secretion, which in turn inhibits viral replication. Furthermore, IFNα secretion was triggered 
by viral RNA which pDCs recognize by TLR7. For activation of pDCs direct cell-cell 
contacts with HCV SGR cells were necessary, most likely for an efficient transfer of viral 
RNA into pDCs, whereas activation by purified exosomes could not be observed. 
Nevertheless, it is possible that via direct contact the viral RNA is transported to pDCs via 
exosomes. 
 
4.2 NK cells and monocytes respond to Hepatitis C Virus subgenomic 
replicon cells  
4.2.1  PBMCs secrete a broad range of cytokines and chemokines in response to 
HCV SGR cells 
Having characterized the IFNα response of pDCs against HCV SGR cells, it was 
investigated if further cytokines or chemokines are secreted by PBMCs in co-culture with 
HCV SGR cells. To this end a Luminex assay was performed in which 50 cytokines and 
chemokines were measured. Next to the co-culture of Huh-7 Con1 cells with PBMCs also 
supernatants from the co-culture of Huh-7 JFH cells with PBMCs were included, which 
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secrete less viral RNA and where no IFNα was detected in previous experiments (Fig. 4-
3). The results of the Luminex assay are summarized in a heat map in Fig. 4-10. It was 
observed that several cytokines and chemokines were secreted in co-culture of PBMCs 
with Huh-7 Con1 cells as well as with Huh-7 JFH cells. The cytokine concentrations were 
mostly higher in Huh-7 Con1 co-cultures, indicating that these cells cause a stronger 
PBMC response. Nevertheless, also Huh-7 JFH cells activated PBMCs, despite the lack of 
IFNα secretion shown before. 
In the following the cytokines and chemokines will be described that were detected in co-
culture of Huh-7 Con1 cells and PBMCs. Pro-inflammatory cytokines IL-6 and TNFα were 
secreted. Besides IFNα (which confirmed previous ELISA data), also IFNγ was produced 
in the co-culture, indicating that also NK cells contribute to the response against HCV SGR 
cells. Moreover, several chemokines were detected that hinted towards a role of 
monocytes: IL-8, MCP1 (monocyte chemotactic protein 1), IP-10 (Interferon gamma-
induced protein 10), MIP-1α (macrophage inflammatory protein 1-alpha), MIP-1β 
(macrophage inflammatory protein 1-beta). All of them can be secreted by monocytes, but 
also other cell types are known to produce these chemokines. In consequence, it was 
further analyzed in how far NK cells and monocytes play a role in the anti-viral response. 
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Fig. 4-10 PBMCs secrete a broad range of cytokines and chemokines in response to HCV SGR cells 
Huh-7 cells (naïve, Con1 or JFH) were co-cultured with PBMCs overnight and the supernatant was analyzed 
by Luminex assay. Supernatant from different Huh-7 cells or PBMCs alone were used as controls (n=4). For 
quantification a standard curve for each cytokine was determined. Data are shown as the percentage of the 
highest standard of each cytokine. 
 
4.2.2  NK cells secrete IFNγ in response to HCV SGR cells 
Following the results of the Luminex assay, IFNγ secretion was also analyzed by ELISA. 
IFNγ was detected in the co-culture of the HCV SGR cell line Huh-7 Con1 with PBMCs 
(Fig. 4-11 A). Neither Huh-7 nor cured Con-1 cells triggered IFNγ production by PBMCs. 
To confirm that NK cells within the PBMC fraction produced IFNγ, NK cells were depleted 
from PBMCs before addition to Huh-7 Con1 cells. After NK cell depletion no IFNγ was 
detected anymore (Fig. 4-11 B). However, in contrast to pDC findings purified NK cells co-
cultured with Huh-7 Con1 cells did not secrete IFNγ (Fig. 4-11 C), indicating that NK cells 
indirectly responded to HCV SGR cells. 
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Fig. 4-11 NK cells secrete IFNγ in response to HCV SGR cells 
(A) Huh-7 cells were co-cultured with PBMCs overnight and IFNγ was measured by ELISA. (B) IFNγ levels in 
co-cultures with PBMCs or with PBMCs depleted from NK cells (PBMC -NK). (C) IFNγ levels in co-cultures 
with purified NK cells (n=3). nd = not detected. 
 
4.2.3 Validation of chemokine expression in response to HCV SGR cells 
To confirm secretion of the chemokines detected in the Luminex assay (Fig. 4-12 A), 
expression of certain chemokines was additionally analyzed by qPCR. Compared to the 
co-culture of Huh-7 cells with PBMCs, all tested chemokines (IL-8, MCP-1, IP-10, MIP-1α 
and MIP-1β) were significantly up-regulated in co-cultures of Huh-7 Con1 cells with 
PBMCs on mRNA level (Fig. 4-12 B). These findings further confirmed that also 
monocytes might play a role in the response against HCV SGR cells. 
 
 
Fig. 4-12 PBMCs secrete multiple chemokines in response to HCV SGR cells 
(A) Protein levels of selected chemokines from the Luminex assay are depicted (n=4). (B) Huh-7 (naïve or 
Con1) were co-cultured with PBMCs for 8h. RNA was extracted and qPCR was performed to quantify RNA 
levels of chemokines (n=3). 
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4.2.4 IL-8 is secreted by HCV SGR cells in co-culture with PBMCs 
As shown before, several chemokines that can be secreted by monocytes were detected 
in the co-culture of Huh-7 Con1 cells with PBMCs. To identify if certain chemokines are 
secreted by monocytes or by HCV SGR cells, intracellular staining of IL-8 as one factor 
was done and analyzed by flow cytometry. Huh-7 cells were CFSE labeled prior to PBMC 
addition and monocytes were identified by CD14 expression. While in the co-culture of 
Huh-7 cells and PBMCs no IL-8 positive cells were detected (Fig. 4-13 A), 34% of Huh-7 
Con1 cells became IL-8 positive in co-culture with PBMCs (Fig. 4-13 B). In contrast, only a 
very low percentage of monocytes showed IL-8 (not significant). Quantification of IL-8 
positive Huh-7 cells as well as the MFI for IL-8 are shown in Fig. 4-13 C and D. 
Taken together this observation demonstrates that IL-8 is not secreted by monocytes, but 
by Huh-7 Con1 cells. Apparently, anti-viral actions by PBMCs also cause a response 
within HCV SGR cells, which secrete the chemokine IL-8 to attract further immune cells. 
Nevertheless, (although not investigated) other chemokines might be secreted by 
monocytes. Importantly, this flow cytometry experiments by chance revealed another 
interesting observation about the role of monocytes, which will be described below. 
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Fig. 4-13 IL-8 is secreted by HCV SGR cells in co-culture with PBMCs 
Huh-7 cells (A) or Huh-7 Con1 cells (B) were stained with CFSE and co-cultured with PBMCs. After 14 h of 
co-culture, Brefeldin A (1 μg/ml) was added and cells were incubated for further 6 h. Monocytes were stained 
with a CD14 antibody; cells were fixed with 1.5% PFA and permeabilized using 0.1% Saponin. Intracellular 
IL-8 was stained with an IL-8 antibody and cells were analyzed by flow cytometry. In the left plots in (A) and 
(B) gates were set to identify monocytes (black) and Huh-7 cells (green). Both populations are depicted in 
the right plot to analyze which cells were positive for IL-8. Quantification of IL-8 positive Huh-7 cells (C) and 
the respective MFI (D) are shown (n=3). Plots from one representative experiment are shown in (A) and (B). 
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4.2.5 Monocytes take up HCV SGR cells 
While monocytes did not secrete IL-8, it was observed that monocytes turned CFSE 
positive in co-culture of CFSE-stained Huh-7 Con1 cells with PBMCs (compare top left 
quadrant Fig. 4-13 A and B). This finding was further investigated: Huh-7 cells were 
stained with CFSE and then co-cultured with PBMCs. However, no Brefeldin was added in 
this set of experiments, as no intracellular staining was performed. After overnight co-
culture with CFSE-stained Huh-7 cells, monocytes were CFSE negative (Fig. 4-14 A, left 
plot Q1). Strikingly, in the co-culture of CFSE-stained Huh-7 Con1 cells with PBMCs nearly 
all monocytes turned CFSE positive (Fig. 4-14, right plot Q2).  
In order to analyze why monocytes became CFSE positive, ImageStream analysis was 
performed. ImageStream combines flow cytometry with microscopy, so that a picture is 
taken of every cell that is running through the flow chamber. Thereby, it became clear that 
monocytes take up small particles derived from Huh-7 Con1 cells (Fig. 4-14 B, lower 
panel, Fig. 4-15). In contrast, the few CFSE positive monocytes that appeared in the co-
culture with Huh-7 cells did not internalize material from these cells but only were in close 
contact (Fig. 4-14 B, upper panel). The size of the particles taken up from Huh-7 Con1 
cells ranged from 1.8-3.3 µm in diameter, suggesting that activated PBMCs induced 
apoptosis of HCV SGR cells. Induction of apoptosis was supported by the observation that 
the number of Huh-7 Con1 cells significantly dropped compared to the number of Huh-7 
cells in co-culture with PBMCs (shown in Fig. 4-14 A Q4, quantified in Fig. 4-14 C). This 
was determined by calculating the ratio of Huh-7 cells and monocytes. At the start of the 
co-culture approximately 1.5 x 105 Huh-7 cells and 1 x 105 monocytes were present. While 
the number of Huh-7 control cells and monocytes remained constant, the number of Huh-7 
Con1 cells clearly decreased. Thus the ratio of Huh-7 Con1 cells and monocytes 
significantly dropped.  
In summary, these findings proved that monocytes are involved in the response against 
HCV SGR cells. 
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Fig. 4-14 Monocytes take up HCV SGR cells 
CFSE-stained Huh-7 cells were co-cultured with PBMCs overnight. (A) Analysis of CFSE distribution in 
relation to monocytes (CD14
+
). (B) Uptake of Huh-7 cells by monocytes depicted by ImageStream analysis. 
(C) Ratio between Huh-7 cells and monocytes after co-culture based on flow cytometry analysis in (A) (n=3). 
Plots from one representative experiment are shown in (A) and (B). 
 
 
Fig. 4-15 ImageStream analysis of the uptake of HCV SGR cells by monocytes 
CFSE-stained Huh-7 Con1 cells were co-cultured with PBMCs overnight. Monocytes were stained by CD14 
antibody. Uptake of Huh-7 Con1 cells by monocytes is depicted by ImageStream analysis. Each line 
represents an independent cellular event. 
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4.2.6 HCV SGR cells with different backgrounds are taken up by monocytes 
To quantify the uptake of Huh-7 Con1 cells by monocytes two parameters were measured 
by flow cytometry. On the one hand the percentage of CFSE positive monocytes was 
determined, on the other hand the CFSE MFI of the whole monocyte population was 
measured. Analysis of these data showed that the uptake of Huh-7 Con1 cells by 
monocytes within PBMCs was significantly higher compared to Huh-7 and cured Con1 
cells (Fig. 4-16 A, B). Moreover, to confirm that the uptake not only occurs with this 
specific Huh-7 Con1 clone, experiments were repeated with another cell line and another 
HCV genotype (Huh-6 JFH). Again, uptake of Huh-6 JFH cells was significantly increased 
compared to Huh-6 or cured JFH cells (Fig. 4-16 C, D).  
 
4.2.7 HCV infected cells are taken up by monocytes 
Next to HCV SGR cells, the uptake was also tested with truly HCV infected cells. Indeed, 
also particles from Huh-7.5 cells infected with the JC1 HCV virus were internalized by 
monocytes. Importantly, this proof of principle demonstrated that the previous observations 
with HCV SGR cells were not due to artifacts of HCV SGR cells and that the results are 
comparable to HCV infected cells. 
 
4.2.8 Monocytes do not take up Dengue Virus and Hepatitis A Virus SGR cells 
Having observed that different HCV SGR cells and HCV infected cells were taken up by 
monocytes, Dengue Virus (DV) and Hepatitis A Virus (HAV) SGR cells were analyzed in 
addition. Neither DV nor HAV SGR cells induced an uptake by monocytes in the co-culture 
with PBMCs (Fig. 4-17). This indicated that the PBMC activation observed with HCV SGR 
cells is specific for HCV, as SGR cells from other RNA viruses from the same family (DV) 
or with the same tropism (HAV) do not trigger PBMC activation. 
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Fig. 4-16 Different HCV SGR cells and HCV infected cells are taken up by monocytes 
PBMCs were co-cultured overnight with various CFSE-stained Huh cells and the percentage of CFSE 
positive monocytes and the CFSE MFI of monocytes were determined by flow cytometry. (A, B) Co-cultures 
of PBMCs with Huh-7 cells (Con1=HCV genotype 1b) (n=3). (C, D) Co-cultures of PBMCs with Huh-6 cells 
(JFH=HCV genotype 2a) (n=3). (C) Co-cultures of PBMCs with Huh-7.5 cells or with HCV infected Huh-7.5 
cells (Huh-7.5 + JC1) (n=2). 
 
 
 
Fig. 4-17 Dengue Virus and Hepatitis A virus SGR cells are not taken up by monocytes 
PBMCs were co-cultured overnight with CFSE-stained Huh-7 cells and various Huh-7 SGR cells (Con1 
(HCV), Dengue Virus (DV) and Hepatitis A virus (HAV)). Percentage of CFSE positive monocytes (A) and 
the CFSE MFI of monocytes (B) were determined by flow cytometry (n=3). 
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4.2.9 Monocyte activation markers CD80 and CD86 are up-regulated in co-culture 
with HCV SGR cells 
Previous results demonstrated that monocytes were taking up particles from HCV SGR 
cells in co-culture with PBMCs. However, it was not clear if monocytes have an active role 
in this process or if monocytes only clear remnants of HCV SGR cells. To investigate if 
monocytes were activated in the co-culture, monocytes were stained for their activation 
markers CD80 and CD86 and analyzed by flow cytometry. Strikingly, most of the 
monocytes showed up-regulation of CD80 and CD86 in co-culture of Huh-7 Con1 cells 
with PBMCs, but not with Huh-7 cells (Fig. 4-18), implying that monocytes play an active 
role in the anti-viral response against HCV SGR cells. 
 
 
Fig. 4-18 Monocytes are activated in co-cultures of HCV SGR cells with PBMCs 
Huh-7 or Huh-7 Con1 cells were co-cultured with PBMCs overnight. Cells were harvested, stained with CD14 
antibody to gate on monocytes and with antibodies against the activation markers CD80 (A, B) and CD86 (C, 
D). CD80 and CD86 positive cells and the MFI of monocytes were analyzed by flow cytometry (n=3). 
 
In summary, in this part it was shown that next to pDCs also NK cells contribute to the anti-
viral response by IFNγ secretion. Secondly, also monocytes contribute as monocytes are 
taking up HCV SGR cells and display up-regulation of activation markers CD80 and CD86. 
Moreover, several chemokines are secreted by PBMCs in co-culture with HCV SGR cells 
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and in turn, also HCV SGR cells are triggered by PBMCs to further attract immune cells 
via secretion of IL-8. Furthermore, the activation of innate immune cells is specific for HCV 
SGR cells, as DV and HAV SGR were not taken up by monocytes. 
 
4.3 pDCs and NK cells promote uptake of Hepatitis C Virus 
subgenomic replicon cells by monocytes 
4.3.1  Purified monocytes are less efficient in uptake of HCV SGR cells compared to 
monocytes within PBMCs 
As described above, in co-cultures of HCV SGR cells with PBMCs a large proportion of 
monocytes internalized particles from HCV SGR cells. That raised the question, if this 
phenotype was caused by monocytes or if additional immune cells were required. Thus, 
monocytes were MACS-purified and co-cultured with CFSE-stained Huh-7 Con1 cells. The 
uptake of Huh-7 Con1 cells by purified monocytes was measured by flow cytometry. Only 
25.4% of monocytes became CFSE positive in co-culture with Huh-7 Con1 cells, which 
was significantly more than in co-culture with Huh-7 cells (6%) (Fig. 4-19). However, 
compared to monocytes within PBMCs (83.6% of monocytes CFSE positive), the 
percentage was clearly lower. Hence, purified monocytes are able to induce uptake of 
HCV SGR cells, but the effect is considerably stronger if other immune cells are present. 
 
 
Fig. 4-19 Purified monocytes are less efficient in uptake of HCV SGR cells 
Purified monocytes (Mono) or PBMCs were co-cultured with CFSE-stained Huh-7 or Huh-7 Con1 cells 
overnight. Percentage of CFSE positive monocytes (A) and the CFSE MFI of monocytes (B) were 
determined by flow cytometry (n=5). 
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4.3.2  Purified monocytes display only slight up-regulation of CD80 and CD86 in 
response to HCV SGR cells 
In another approach to analyze to what extent purified monocytes are activated by HCV 
SGR cells, monocyte activation markers CD80 and CD86 were analyzed again. While 
CD80 and CD86 were strongly up-regulated on monocytes in co-culture of Huh-7 Con1 
cells with PBMCs (Fig. 4-18), no significant increase in surface expression of CD80 and 
CD86 was observed between the co-culture of purified monocytes with Huh-7 or with Huh-
7 Con1 cells (Fig. 4-20, note the different scale compared to Fig. 4-18). Nevertheless, a 
slight increase in co-culture with Huh-7 Con1 cells compared to Huh-7 was observed. In 
line with the uptake experiments above this again indicated that purified monocytes are 
activated to some extent, but that other immune cells contribute to monocyte activation. 
 
 
Fig. 4-20 Purified monocytes only slightly up-regulate CD80 and CD86 in response to HCV SGR cells 
Huh-7 or Huh-7 Con1 cells were co-cultured with purified monocytes overnight. Cells were harvested, 
stained with CD14 antibody to gate on monocytes and with antibodies against the activation markers CD80 
(A, B) and CD86 (C, D). CD80 and CD86 positive cells and the MFI of monocytes were analyzed by flow 
cytometry (n=3). 
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4.3.3  pDCs and NK cells contribute to uptake of HCV SGR cells by monocytes 
Since it was observed that activation of purified monocytes in co-culture with HCV SGR 
cells was lower compared to monocytes within PBMCs, it was speculated that pDCs and 
NK cells might play a role for the uptake by monocytes as both were shown to secrete 
IFNα (pDCs, Fig. 4-1) or IFNγ (NK cells, Fig. 4-11) in response to HCV SGR cells. To test 
this, pDCs and NK cells were depleted from PBMCs and the uptake of Huh-7 Con1 cells 
by monocytes was analyzed. Interestingly, neither depletion of pDCs nor depletion of NK 
cells alone reduced the uptake. However, when pDCs and NK cells were both depleted, 
the uptake significantly dropped to levels similar to the uptake by purified monocytes (Fig. 
4-21). These results demonstrated that both, pDCs and NK cells promote the uptake of 
HCV SGR cells by monocytes. 
 
 
Fig. 4-21 pDCs and NK cells contribute to uptake of HCV SGR cells by monocytes 
CFSE-stained Huh-7 Con1 cells were co-cultured overnight with PBMCs, purified monocytes (Mono), 
PBMCs depleted from pDCs (PBMC -pDC), from NK cells (PBMC -NK) or from pDCs and NK cells (PBMC -
pDC -NK ). Percentage of CFSE positive monocytes (A) and the CFSE MFI of monocytes (B) were 
determined by flow cytometry (n=3). 
 
4.3.4  IFNα and IFNγ boost the uptake of HCV SGR cells by monocytes 
As it was found that pDCs and NK cells promote the uptake of HCV SGR by monocytes, 
next it was analyzed if the respective interferons produced by these cells were sufficient to 
increase the uptake by monocytes. Monocytes were purified and co-cultured with CFSE-
stained Huh-7 cells in the presence of IFNα or IFNγ. Concentrations of interferons were 
derived from the amount measured in the co-culture of HCV SGR cells with PBMCs. 
Indeed, both interferons significantly boosted the uptake of Huh-7 Con1 cells (Fig. 4-22 A, 
B). In the presence of IFNα 62.7% of monocytes turned CFSE positive, 40.6% in presence 
of IFNγ (25.4% without interferon). Interferons had only a minor effect on the uptake of 
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Huh-7 control cells. In order to analyze if interferons acted on monocytes or on Huh-7 
Con1 cells, either monocytes or Huh-7 Con1 cells were pre-incubated with IFNα overnight 
before setting up the co-culture. However, neither pre-incubation of monocytes with IFNα 
(Fig. 4-22 C, D) nor of Huh-7 Con1 cells (Fig. 4-22 E, F) was sufficient to significantly 
boost the uptake. This indicated that IFNα needs to act on monocytes as well as on Huh-7 
Con1 cells during the co-culture period to promote uptake. 
 
Fig. 4-22 Interferons boost the uptake of HCV SGR cells by monocytes 
(A, B) CFSE-stained Huh-7 or Huh-7 Con1 cells were co-cultured overnight with purified monocytes (Mono) 
in the presence of IFNα (700 pg/ml) or IFNγ (7 ng/ml). (n=4.) (C, D) Purified monocytes were incubated with 
IFNα overnight, IFNα was removed by washing and monocytes were added to CFSE-stained Huh-7 Con1 
cells for overnight co-culture (n=2). (E, F) CFSE-stained Huh-7 Con1 cells were incubated with IFNα 
overnight, IFNα was removed by washing and purified monocytes were added for overnight co-culture (n=2). 
Percentage of CFSE positive monocytes (A, C, E) and the CFSE MFI of monocytes (B, D, F) were 
determined by flow cytometry. 
 
Next to addition of recombinant interferons to purified monocytes, the role of interferons for 
the uptake by monocytes was also investigated in a time course experiment. CFSE-
stained Huh-7 Con1 cells were co-cultured with PBMCs and every 2 hours supernatant 
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and cells were collected to measure IFNα and IFNγ levels by ELISA and monocyte uptake 
by flow cytometry (Fig. 4-23). After 6 h around 30% of monocytes were CFSE positive (this 
was in range with the uptake by purified monocytes), while no IFNα and low amounts of 
IFNγ were detected. From this time point on monocyte uptake steadily increased and after 
14 h 83% of monocytes were CFSE positive. The increase in monocyte uptake correlated 
with increased levels of IFNγ levels after 8 h and especially after 10 h. In this time range 
also IFNα was detected. To sum up, monocyte uptake began before secretion of 
interferons, thus confirming previous results in which purified monocytes were also able to 
take up HCV SGR cells (Fig. 4-19). However, as soon as interferons were released the 
uptake was significantly increased, again indicating that interferons boost the uptake by 
monocytes. 
 
 
Fig. 4-23 Time course analysis of monocyte uptake and interferon secretion 
CFSE-stained Huh-7 Con1 cells were co-cultured with PBMCs. After every 2 h supernatants and cells were 
harvested and IFNα and IFNγ levels were measured by ELISA. Monocyte uptake was analyzed by flow 
cytometry (n=1). 
 
4.3.5  Monocytes are required for secretion of IFNγ by NK cells 
While previous experiments revealed that pDCs and NK cells influence the uptake of HCV 
SGR cells by monocytes, it has also been published that monocytes influence NK cells in 
the context of an anti-viral response against HCV82. Hence, monocytes were depleted from 
PBMCs before co-culture with Huh-7 Con1 cells and interferon secretion was analyzed. 
IFNα production by pDCs was not affected by monocyte depletion (Fig. 4-24 A). In 
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contrast, IFNγ secretion by NK cells was almost completely lost (Fig. 4-24 B). Hence, it 
was confirmed that monocytes influence the NK cell response in co-culture with HCV SGR 
cells. Moreover, it became clear that not only pDCs and NK cells act on monocytes, but 
that also monocytes have an effect on NK cells. In addition, this explained why purified NK 
cells did not respond with IFNγ secretion in co-culture with HCV SGR cells. 
 
 
Fig. 4-24 IFNγ secretion by NK cells is dependent on monocytes 
Huh-7 Con1 cells were co-cultured with PBMCs or with PBMC depleted from monocytes (-Mono) overnight. 
Supernatants were collected and measured for IFNα (A) and IFNγ (B) level by ELISA (n=3). 
 
In summary, in this part it was shown that purified monocytes are able to respond to HCV 
SGR cells. However, their activation is significantly increased when pDCs or NK cells are 
present and secrete their respective interferons. Moreover, monocytes in turn also 
influence the response of NK cells, as IFNγ secretion by NK cells is dependent on 
monocytes. The data indicated that multiple innate immune cells interact with each other in 
the response against HCV SGR cells. 
 
4.4 Interaction of innate immune cells leads to apoptosis of HCV SGR 
cells 
4.4.1  HCV SGR cells are killed by PBMCs 
Following the detailed analysis of the uptake of HCV SGR cells by monocytes and how 
pDCs and NK cells contribute to this, it was analyzed why the small particles visualized in 
ImageStream analysis (Fig. 4-14, Fig. 4-15) occur. These particles and the observation 
that the number of HCV SGR cells decreased during co-culture with PBMCs (Fig. 4-14 C) 
led to the hypothesis that HCV SGR cells might be killed by PBMCs. To test this 
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hypothesis an LDH release assays was performed. Huh-7 control cells were not killed, but 
around 35% of Huh-7 Con1 cells were killed in co-culture with PBMCs (Fig. 4-25 A). In 
order to analyze if Huh-7 Con1 cells underwent apoptosis, cleavage of PARP was 
analyzed by Western Blot, as cleaved PARP determines the final irreversible step of 
apoptosis. Cleaved PARP was only detected in the co-culture of Huh-7 Con1 cells with 
PBMCs (Fig. 4-25 B), indicating that PBMCs drive HCV SGR cells into apoptosis. Thus, 
the particles detected within monocytes in previous experiments were apoptotic vesicles 
from HCV SGR cells. 
 
 
Fig. 4-25 HCV SGR cells are killed by PBMCs 
Huh-7 or Huh-7 Con1 cells were co-cultured with PBMCs overnight. Supernatants were collected and LDH 
release was measured (A) (n=4). Cells were lysed and analyzed for cleavage of PARP by Western Blot (B). 
In the upper panel in (B) one representative experiment is depicted, the lower panel shows quantification of 
n=3-4. 
 
4.4.2  Caspase inhibition blocks killing and uptake of HCV SGR cells 
PARP cleavage already indicated that HCV SGR cells are driven into apoptosis by 
PBMCs. This was further analyzed by blocking of caspases, as successive caspase 
activation leads to apoptosis of target cells. When all caspases were inhibited by a pan-
caspase inhibitor, significantly less Huh-7 Con1 cells were killed by PBMCs and, 
accordingly, less monocytes became CFSE positive (Fig. 4-26). To specifically block a 
caspase in the target cell, a caspase-8 inhibitor was used. Although not as efficient as the 
pan-caspase block, killing and uptake of Huh-7 Con1 cells was still significantly decreased. 
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Blocking caspase-1 was used as control, as caspase-1 is not involved in apoptosis, but 
plays a role in inflammasome activation. Indeed, caspase-1 inhibition had no effect on 
killing and uptake of HCV SGR cells by PBMCs. Taken together the data demonstrated 
that PBMCs induce apoptosis in HCV SGR cells. 
 
 
Fig. 4-26 Caspase inhibition blocks killing and uptake of HCV SGR cells 
Huh-7 Con1 cells were co-cultured with PBMCs in presence of pan-caspase inhibitor Z-VAD-FMK (20 μM), 
caspase-8 inhibitor Z-IETD-FMK (20 μM) or caspase-1 inhibitor Z-YVAD-FMK (20 μM). After overnight 
incubation LDH release was measured in the supernatant (A), percentage of CFSE positive monocytes (B) 
and the CFSE MFI of monocytes (C) were determined by flow cytometry. 
 
4.4.3 Interaction of innate immune cells is required for killing of HCV SGR cells 
Having observed that HCV SGR cells are driven into apoptosis by PBMCs, the question 
raised which cells within PBMCs trigger apoptosis of HCV SGR cells. Previous results 
showed that NK cells, pDCs and monocytes were activated in co-culture with HCV SGR 
cells. Thus, these cells were purified and co-cultured with Huh-7 Con1 cells. LDH release 
assays were performed to detect apoptosis. However, neither purified NK cells, nor pDCs 
or monocytes were able to efficiently kill Huh-7 Con1 cells. In contrast, recombination of 
these cell types led to killing of Huh-7 Con1 cells, although not as many cells were killed 
as by complete PBMCs (14.1% vs 34.1%, Fig. 4-27 A). The lower percentage of killed 
Huh-7 Con1 cells might be due to impaired functions of immune cells as a consequence of 
the purification process. Nevertheless, the experiment demonstrated that interaction of 
different innate immune cells is necessary and sufficient for killing of HCV SGR cells. 
To confirm that multiple innate immune cells contribute to killing of HCV SGR cells, NK 
cells, pDCs or monocytes were depleted from PBMCs and killing activity was measured by 
an LDH release assay. Independent of which cell type was depleted, the percentage of 
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killed Huh-7 Con1 cells slightly decreased (although not significantly) (Fig. 4-27 B), 
indicating that each cell type plays a role in induction of apoptosis of HCV SGR cells. In 
line with this, depletion of both, NK cells and pDCs significantly reduced cytotoxicity, 
highlighting the need for combined activation and interplay of different innate immune cells 
to kill HCV SGR cells. 
 
Fig. 4-27 Interaction of innate immune cells is required for killing of HCV SGR cells 
(A) Huh-7 Con1 cells were co-cultured overnight with PBMCs, purified NK cells (NK), purified pDCs (pDC), 
purified monocytes (Mono) or a recombination of NK cells, pDCs and monocytes (NK +pDC +Mono). 
Supernatants were collected and LDH release was measured (n=3). (B) Huh-7 Con1 cells were co-cultured 
overnight with PBMCs, PBMCs depleted from from NK cells (-NK), from pDCs (-pDC), from monocytes (-
Mono) or from pDCs and NK cells (-NK -pDC). Supernatants were collected and LDH release was measured 
(n=3). 
 
4.4.4  NK cells display surface expression of CD69, CD25 and TRAIL in co-culture of 
HCV SGR cells with PBMCs 
As the above described experiments showed that interaction of innate immune cells is 
required to cause apoptosis in HCV SGR cells, next the mechanisms of triggering 
apoptosis were investigated. NK cells were more closely examined as they are known to 
be able to kill virus infected cells. Thus, NK cells were analyzed for expression of 
activation markers in the co-culture of Huh-7 Con1 cells with PBMCs by flow cytometry. A 
strong up-regulation of the activation markers CD69 and CD25 on NK cells was observed 
in co-culture of Huh-7 Con1 cells and PBMCs (Fig. 4-28 A, B). In combination with the 
previously described IFNγ secretion by NK cells (Fig. 4-11), this observation underlined 
the hypothesis that NK cells are able to induce apoptosis in HCV SGR cells. Indeed, up-
regulation of TRAIL was found on NK cells which is known to induce apoptosis in target 
cells (Fig. 4-28 C). Interestingly, only a subpopulation of NK cells expressed TRAIL (Fig. 4-
28 right plot), suggesting that a specific subtype of NK cells is responsible for apoptosis 
induction in HCV SGR cells. 
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4.4.5  Blocking TRAIL reduces killing and uptake of HCV SGR cells 
In order to analyze if the observed TRAIL expression on NK cells causes apoptosis in HCV 
SGR cells, Huh-7 Con1 cells were co-cultured with PBMCs in presence of a TRAIL 
blocking antibody. Strikingly, blocking TRAIL significantly decreased cytotoxicity of PBMCs 
against Huh-7 Con1 cells (Fig. 4-29 A). In consequence, also the uptake by monocytes of 
CFSE labeled Huh-7 Con1 cells was reduced (Fig. 4-29 B, C). Addition of an IgG control 
antibody had no influence on killing and uptake of Huh-7 Con1 cells. Thus, it was proven 
that TRAIL expression on NK cells drives apoptosis of HCV SGR cells. 
 
 
Fig. 4-28 CD69, CD25 and TRAIL are expressed on NK cells in co-culture with HCV SGR cells 
Huh-7 or Huh-7 Con1 cells were co-cultured with PBMCs overnight. Cells were harvested, stained with CD3 
and CD56 antibody to gate on NK cells (CD3
-
 CD56
+
) and with antibodies against the activation markers 
CD69 (A) and CD25 (B) and against the apoptosis inducing TRAIL (C). MFI of NK cells for each surface 
protein was analyzed by flow cytometry (n=4). Right plots in (C) depict one representative experiment, in 
which TRAIL expression on NK cells was measured in co-culture of PBMCs with Huh-7 cells (top) or with 
Huh-7 Con1 cells (bottom). 
 
 
Fig. 4-29 Blocking TRAIL inhibits killing and uptake of HCV SGR cells 
Huh-7 Con1 cells were co-cultured with PBMCs in presence of a TRAIL blocking antibody or an IgG control 
antibody (each 10 µg/ml). After overnight incubation LDH release was measured in the supernatant (A), 
percentage of CFSE positive monocytes (B) and the CFSE MFI of monocytes (C) were determined by flow 
cytometry (n=4). 
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4.4.6  TRAIL receptor expression is similar in HCV SGR cells and control cells 
Since HCV SGR cells were driven into apoptosis by TRAIL expression on NK cells, it was 
investigated if susceptibility of HCV SGR cells is due to overexpression of TRAIL 
receptors. To this end, RNA from Huh-7 and Huh-7 Con1 cells was extracted and 
analyzed for TRAIL receptor expression by qPCR. All known TRAIL receptors were 
analyzed, the pro-apoptotic receptors DR4 (death receptor 4) and DR5 as well as the anti-
apoptotic receptors DcR1 (decoy receptor 1) and DcR2. However, none of the TRAIL 
receptors were differentially expressed (mRNA) between Huh-7 and Huh-7 Con1 cells 
(Fig. 4-30 A-C). DcR1 was not expressed (data not shown). 
 
 
Fig. 4-30 TRAIL receptor expression is comparable in Huh-7 and Huh-7 Con1 cells 
Huh-7 and Huh-7 Con1 cells were analyzed for expression of pro-apoptotic TRAIL receptors DR4 (A) and 
DR5 (B) and for anti-apoptotic TRAIL receptor DcR2 (C) by qPCR. 
 
4.4.7  Activated PBMCs target HCV SGR cells, but not naïve Huh-7 cells 
Following the observation of similar TRAIL receptor expression in Huh-7 and Huh-7 Con1 
cells, it was examined if PBMCs pre-activated by HCV SGR cells could also target Huh-7 
control cells. This was investigated in a triple co-culture of Huh-7, Huh-7 Con1 cells and 
PBMCs. Before analyzing if also Huh-7 cells are killed in this triple co-culture, it had to be 
proven that PBMCs are activated in this setup. Thus, the triple co-culture was performed 
and different parameters for PBMC activation were measured. IFNα secretion by pDCs, 
IFNγ secretion by NK cells and NK cell activation markers CD25 and CD69 were detected 
in the triple co-culture (Fig. 4-31). Compared to the co-culture of Huh-7 Con1 cells with 
PBMCs the signals were lower for each readout, which can be explained by the lower 
numbers of Huh-7 Con1 cells. In the triple co-culture only half as many Huh-7 Con1 cells 
are present compared to the co-culture of Huh-7 Con1 cells with PBMCs.  
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Having shown that PBMCs are activated in the triple co-culture, it was analyzed if also 
Huh-7 cells are targeted by PBMCs that are stimulated by HCV SGR cells. Therefore, 
Huh-7 Con1 cells were stained with CFSE, Huh-7 cells were stained with CytoRED and 
the triple co-culture with PBMCs was set up. 
 
Fig. 4-31 Innate immune cells are activated in triple co-culture of Huh-7, Huh-7 Con1 and PBMCs 
(A-D) PBMCs were co-cultured overnight with Huh-7, Huh-7 Con1 or with Huh-7 and Huh-7 Con1 cells 
together. Supernatants were harvested and analyzed by ELISA for IFNα (A) and IFNγ (B). Cells were 
harvested and CD25 (C) and CD69 (D) expression on NK cells was analyzed by flow cytometry (n=2). 
 
To analyze if only Huh-7 Con1 or also Huh-7 cells were killed, it was measured by flow 
cytometry whether monocytes turned CFSE positive or CytoRED positive. As a result 
monocytes became CFSE positive, indicating that Huh-7 Con1 cells were killed. In 
contrast, monocytes did not become CytoRED positive (Fig. 4-32), showing that naïve 
Huh-7 control cells were not driven into apoptosis by PBMCs that were activated in the 
same culture by presence of HCV SGR cells. To exclude an influence of the dyes, staining 
of Huh-7 cells was performed vice versa. Thus, Huh-7 cells were stained with CFSE and 
Huh-7 Con1 cells with CytoRED. Again, only Huh-7 Con1 but not Huh-7 cells were killed 
by PBMCs, as monocytes only became CytoRED positive (Fig. 4-33). Taken together, 
these results demonstrated that PBMCs specifically kill HCV SGR cells, but do not target 
uninfected control cells. 
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Fig. 4-32 Activated PBMCs target HCV SGR cells, but not naïve Huh-7 cells 
CytoRED-stained Huh-7 cells were co-cultured with CFSE-stained Huh-7 Con1 cells and PBMCs overnight. 
The percentage of CytoRED and CFSE positive monocytes (B) as well as the CytoRED and CFSE MFI (C) 
of monocytes were measured (n=3). The gating strategy is depicted in (A). 
 
 
Fig. 4-33 Activated PBMCs target HCV SGR cells, but not naïve Huh-7 cells 
CFSE-stained Huh-7 cells were co-cultured with CytoRED-stained Huh-7 Con1 cells and PBMCs overnight. 
The percentage of CFSE and CytoRED positive monocytes (B) as well as the CFSE and CytoRED MFI (C) 
of monocytes were measured (n=3). The gating strategy is depicted in (A). 
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4.4.8  NK cells adhere stronger to HCV SGR cells compared to Huh-7 cells 
As PBMCs in the triple co-culture with Huh-7 and Huh-7 Con1 cells only targeted the latter 
ones, it was speculated that up-regulation of surface ligands on HCV SGR cells could be 
recognized by PBMCs. Thus, the adherence of PBMCs to Huh-7 and Huh-7 Con1 cells 
were measured by flow cytometry. After overnight co-culture, non-adherent cells were 
washed off and collected. Adherent cells were detached by trypsin treatment and 
separately collected from washed off cells. The percentages of monocytes and NK cells in 
these two fractions were then analyzed by flow cytometry. For monocytes no difference in 
adherence to Huh-7 or Huh-7 Con1 cells was observed, as monocytes per se are strongly 
adherent cells (Fig. 4-34 A). Yet, NK cells displayed stronger adherence to Huh-7 Con1 
cells (Fig. 4-34 B). While in the co-culture with Huh-7 cells more NK cells were found in the 
washed off cells, in co-culture with Huh-7 Con1 cells more NK cells were present in the 
fraction detached by trypsin. Hence, this result supported the hypothesis that ligands on 
HCV SGR cells might be recognized by PBMCs. 
 
 
Fig. 4-34 Adherence of monocytes and NK cells to Huh-7 cells and Huh-7 Con1 cells 
Huh-7 or Huh-7 Con1 cells were co-cultured with PBMCs overnight. Non-adherent cells were washed off and 
adherent cells were detached by trypsin treatment. Both fractions were stained with CD56 antibody to gate 
on NK cells and with CD14 antibodies to gate on monocytes. Percentage of monocytes (A) and NK cells (B) 
in both fractions were determined by flow cytometry (n=3).  
 
4.4.9  Analysis of the surface proteome of HCV SGR cells 
To study the hypothesis of differential expression of surface proteins between HCV SGR 
cells and Huh-7 control cells as a trigger for PBMC activation, the surface proteome of 
both cells was analyzed. In brief, surface proteins were biotinylated, purified by 
streptavidin beads and then analyzed by mass spectrometry. Four proteins were found to 
be significantly up-regulated on Huh-7 Con1 cells compared to Huh-7 cells: SQRDL 
(sulfide quinone reductase-like protein), ACTA1 (alpha-actin-1), RPS6KA3 (ribosomal 
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protein S6 kinase alpha-3). SMPDL3B (sphingomyelin phosphodiesterase acid like 3B) 
(Fig. 4-35 A). Despite multiple efforts to eliminate intracellular proteins, it was impossible to 
completely remove all. Thus, only one of these four proteins in fact is a typical surface 
protein, SMPDL3B. However, this protein was shown to be a negative regulator of innate 
immunity119 and was not further considered to be responsible for activation of innate 
immune cells in co-culture with HCV SGR cells. 
Nevertheless, the surface proteome revealed that CD38 and CD44 were also up-regulated 
on Huh-7 Con1 cells (although not significant). Both proteins were also found in 
unpublished microarray data (AG Lohmann) to be higher expressed in HCV SGR cells. 
Hence, the expression of CD38 and CD44 was analyzed by flow cytometry. Indeed, 
surface expression of both proteins was higher on Huh-7 Con1 cells compared to Huh-7 
cells (Fig. 4-35 B, C). Especially CD38 was of high interest as it is a ligand for CD31 which 
is highly expressed on monocytes. However, neither blocking of CD38 or of CD31 by 
antibodies, nor siRNA mediated knockdown of CD38 had an effect on activation of 
PBMCs. Similarly, also CD44 had no influence (data not shown). In summary, the 
hypothesis that PBMCs recognize HCV SGR cells by expression of specific surface 
proteins could not be substantiated by additional data. 
 
 
Fig. 4-35 Analysis of the surface proteome of HCV SGR cells 
(A) Surface proteins of Huh-7 and Huh-7 Con1 cells were biotinylated, cells were lysed, biotinylated proteins 
were captured by streptavidin beads and analyzed by mass spectrometry. Red dots depict significantly 
differentially expressed proteins (n=1). (B, C) Huh-7 Con1 cells were stained with CD38 (B) or CD44 (C) 
antibodies and analyzed by flow cytometry. Gates were set with Huh-7 cells, one representative experiment 
of n=2 is shown. 
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4.4.10  HCV SGR cells are sensitized towards TRAIL signaling 
Since surface proteome analysis could not explain why PBMCs (activated by HCV SGR 
cells) specifically kill HCV SGR cells but not Huh-7 cells, another hypothesis was tested. 
Previous results indicated that NK cells kill HCV SGR cells by TRAIL expression (Fig. 4-
28, Fig. 4-29), but TRAIL receptor expression was similar in Huh-7 and in Huh-7 Con1 
cells (Fig. 4-30). Thus, it was analyzed if HCV SGR cells per se are more sensitive 
towards TRAIL induced apoptosis. Therefore, Huh-7 Con1 cells were treated with 
recombinant TRAIL and killing of cells was investigated. Strikingly, only Huh-7 Con1 cells, 
but not Huh-7 or cured Con1 cells were killed by recombinant TRAIL (Fig. 4-36 A). 
Interestingly, similar to the co-culture with PBMCs around 30% of cells were killed. In 
contrast to TRAIL, TNFα (same protein family as TRAIL) did not induce cell death (Fig. 4-
36 B), suggesting that the effect is specific for TRAIL. To prove that recombinant TRAIL 
induced apoptosis in Huh-7 Con1 cells, PARP cleavage was analyzed by Western Blot. 
Indeed, cleaved PARP was detected only detected in Huh-7 Con1 cells treated with TRAIL 
(Fig. 4-36 C, D). Finally, the sensitivity of HCV SGR cells towards TRAIL explains why 
activated PBMCs specifically kill HCV SGR cells but not Huh-7 cells. 
 
 
Fig. 4-36 TRAIL induces apoptosis of HCV SGR cells 
(A, B) Huh-7 cells were incubated with recombinant TRAIL (A) or TNFα (B) at the indicated concentrations 
overnight. Cell free supernatants were collected and measured for LDH activity (n=3). (C, D) Huh-7 cells 
were incubated with recombinant TRAIL (100 ng/ml) for the indicated time points and analyzed for cleavage 
of PARP by Western Blot. One representative blot is shown in (C). Quantification of n=2-3 is shown in (D). 
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In summary, the first parts of this work showed that multiple innate immune cells (pDCs, 
NK cells, monocytes) contribute to the response against HCV SGR cells. Eventually, in 
this last part it was demonstrated that the combined activation and interplay of these 
innate immune cells leads to killing and clearance of HCV SGR cells. As a mechanism 
underlying killing, TRAIL expression on NK cells was found to drive apoptosis in HCV SGR 
cells. Importantly, control cells were not targeted as only HCV SGR cells are sensitive 
towards TRAIL. 
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5 Discussion 
Previous studies had shown that ISGs are up-regulated in livers of patients with chronic 
HCV infection. Despite different mechanisms of HCV to interfere with intracellular immune 
responses, somehow interferons must be produced that account for the up-regulation of 
ISGs. Recently, it was discovered that pDCs are able to respond to HCV infected cells or 
to SGR cells by production of IFNα59. In the present study the innate immune response 
against HCV was investigated in detail by co-culturing HCV SGR cells with PBMCs. The 
results demonstrate how the interaction of various innate immune cells enables them to 
elicit an efficient, rapid and specific response against HCV infected cells. While PBMCs 
were able to kill and clear HCV SGR cells (Fig. 4-25, Fig. 4-14), purified subsets of innate 
immune cells were not able to kill HCV SGR cells (Fig. 4-27). Effector mechanisms of 
immune cells exerted in response to HCV SGR cells within complete PBMCS did not occur 
(or were weaker) with purified immune cells. For example, NK cells within PBMCs 
secreted IFNγ (Fig. 4-11 A, B), whereas purified NK cells failed to do so (Fig. 4-11 C). On 
the other hand, monocytes displayed strong up-regulation of activation markers CD80 and 
CD86 within PBMCs (Fig. 4-18), but purified monocytes only showed a minor non-
significant up-regulation (Fig. 4-20). The contribution of individual innate immune cells and 
their interplay in the response against HCV will be discussed below. 
 
5.1 pDC activation in response to HCV SGR cells 
As earlier reports indicated that pDCs respond to HCV infected cells58,59, in a first step to 
establish the experimental setup of the co-culture of HCV SGR cells and PBMCs, IFNα 
secretion was analyzed. Indeed, these earlier studies could be confirmed, since IFNα was 
detected in the co-culture of Huh-7 Con1 cells and PBMCs and absent after pDC depletion 
(Fig. 4-1 A, B). In contrast, cured Con1 cells did not trigger pDCs. Importantly, also purified 
pDCs responded with IFNα secretion in co-culture with Huh-7 Con1 cells (Fig. 4-1 C), 
indicating that pDCs directly recognize HCV replicating cells. 
 
5.1.1 HCV RNA as stimulus for immune cell activation 
Previous reports suggested a role of viral RNA in pDC activation59,118, as IRS661 (a TLR7-
inhibitory sequence) significantly decreased IFNα production. Furthermore, fluorescence in 
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situ hybridization (FISH) experiments showed that 90% of pDCs that carried viral RNA 
were positive for IFNα63. This implied that viral RNA is recognized by TLR7 in pDCs. 
Indeed, it was reported that HCV RNA can be detected by TLR7120. 
Here it was further investigated if in fact viral RNA is responsible for pDC activation. The 
amount of HCV RNA in the supernatant of the co-culture correlated with the levels of IFNα 
secretion by pDCs (Fig. 4-3). Moreover, inhibition of endosomal TLRs by Bafilomycin and 
Chloroquine completely abrogated IFNα production (Fig. 4-4). This underlines that viral 
RNA plays a role in pDC activation. To mechanistically analyze the contribution of viral 
RNA recognition in more detail, the co-culture system was established with murine cells. 
To this end, BMDM from WT, TLR7 KO mice and mutant Unc93b1 mice (which lack 
endosomal trafficking of TLRs) were co-cultured with Hep56D SGR cells. While BMDM 
from TLR7 KO mice displayed reduced cytokine secretion, BMDM from mutant Unc93b1 
mice were not stimulated in co-culture with murine SGR cells (Fig. 4-5). These results 
showed that recognition of viral RNA by TLR7 contributes to stimulation of BMDM. 
However, as BMDM from TLR7 KO mice still produced low amounts of IL-6, also other 
mechanisms of stimulation exist (potentially via recognition of dsRNA by TLR3). 
Experiments with mutant Unc93b1 cells proved that other endosomal TLRs also recognize 
viral RNA, as BMDM from those mice did not respond. 
Next to TLR7, other TLRs recognizing nucleic acids are present in endosomes (TLR 3, 8, 
9 and TLR13 in addition in mice)121. Since TLR8 in mice is not functional122, TLR9 
recognizes DNA123, and TLR13 recognizes bacterial RNA124, TLR3 might sense HCV 
RNA. TLR3 recognizes dsRNA38 and dsRNA occurs as a replication intermediate. 
Therefore, it is possible that a TLR3-dependent activation of BMDMs takes place. 
Furthermore, positive and negative viral ssRNA are secreted by HCV SGR cells27 which 
also indicates that dsRNA could be subjected to immune cells. In fact, the observed 
contribution of TLR3 in the murine system was also shown to play a role in HCV infected 
hepatocytes125. In that study Huh-7.5 cells were stably transfected with TLR3 (TLR3 is 
expressed in primary human hepatocytes). After HCV infection these cells were able to 
sense HCV infection which resulted in NF-κB activation and expression of several 
cytokines and chemokines. Also monocyte derived macrophages were shown to recognize 
HCV dsRNA via TLR3126,127. Transfection of HCV dsRNA into monocyte derived 
macrophages led to expression of type I interferons and increased levels of TLR3. Next to 
TLR3, macrophages were also shown to detect HCV RNA via TLR7 and TLR8128. 
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In summary, the results in this study are in line with other reports and provide further 
evidence that viral RNA is triggering pDC activation via recognition by TLR7. Additionally, 
the murine model suggested a role of TLR3 in recognition of HCV RNA, which was 
confirmed in human cells by further reports. 
 
5.1.2 Transport of viral RNA: exosomes versus cell-cell contact 
As discussed above, activation of innate immune cells depends on recognition of viral 
RNA by TLRs. Logically, the question arises how viral RNA accesses innate immune cells. 
In an earlier study it was reported that viral RNA is secreted from infected cells via 
exosomes63. Other reports however suggested that cell-cell contacts between infected 
cells and immune cells are required for activation59. 
In this work it was addressed in how far these suggested transport routes account for 
trafficking of HCV RNA into immune cells. Hence, exosome release inhibitors GW4869 
and Spiroepoxide were used to analyze the role of exosomes. While GW4869 reduced 
pDC activation in co-culture with Huh-7 Con1 cells (Fig. 4-6 A), Spiroepoxide had no effect 
(Fig. 4-6 C). GW4869 and Spiroepoxide are structurally unrelated, but both act via 
inhibition of neutral sphingomyelinases116,129. Neutral sphingomyelinases regulate the 
biosynthesis of the sphingolipid ceramide, which triggers the budding of endosomes into 
MVB116. As both inhibitors act via the same mechanism, it was surprising to obtain varying 
results with the different inhibitors. In another approach to target exosome release, 
Rab27a was knocked down, which is linked to exosome release117. Knockdown of Rab27a 
significantly reduced IFNα secretion (Fig. 4-6 D), but was not as potent as GW4869. Due 
to the varying results with the inhibitors and the siRNA treatment, no clear conclusion on 
the role of exosomes could be drawn at this stage, but exosome trafficking pathway seem 
to contribute to pDC activation. 
Hence, exosomes were purified from HCV SGR cells and it was analyzed if they trigger 
IFNα production. Despite high levels of HCV RNA in purified exosomes (144x more 
compared to the co-culture) no activation of pDCs was observed (Fig. 4-7). In contrast, in 
a previous study isolated exosomes from HCV SGR cells were able to stimulate purified 
pDCs63. However, here exosomes were incubated with complete PBMCs, while Dreux et 
al. used purified pDCs. Thereby, all exosomes can be taken up by pDCs, while in the 
setup with complete PBMCs other cell types might shield the low abundant pDCs from 
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exosomes. In conclusion, exosomal transport of viral RNA seems to allow activation of 
pDCs. However, as in the direct co-culture of HCV SGR cells with PBMCs lower amounts 
of viral RNA were sufficient to trigger pDCs (144x less compared to purified exosomes in 
this study, over 150x fold less compared to purified exosomes in the study of Dreux et 
al.63), direct cell-cell contacts seem to play a superior role in activation of innate immune 
cells via transfer of viral RNA. Still, it is possible that the transfer of viral RNA during cell-
cell contacts is mediated by exosomes, as exosomes were shown to carry viral RNA (Fig. 
4-7). It could be speculated that direct contact between infected cells and pDCs triggers a 
secretion of exosomes in infected cells. Due to the close contact, exosomes containing 
viral RNA could be directly subjected to pDCs. 
The conclusion that cell-cell contacts are of high importance was supported by further 
results of this study. In transwell experiments where PBMCs were separated from HCV 
SGR cells by a membrane (with 1 µm large pores which means exosomes could pass) 
IFNα was not measured (Fig. 4-8 A). Also in experiments where the co-culture of HCV 
SGR cells was performed with mechanical shaking to prevent formation of cell-cell 
contacts IFNα was significantly reduced, while shaking did not impair R848 stimulation of 
pDCs (Fig. 4-8 B). Moreover, in line with a previous study118, blocking CD81 and CD9 
inhibited IFNα secretion by pDCs (Fig. 4-9). CD81 and CD9 both are part of the 
tetraspanin protein family and interact with each other130. Interestingly, pDCs highly 
express CD81 and CD9, while Huh-7.5 cells show high CD81 and low CD9 levels118. Of 
note, despite expression of the HCV entry receptor CD81 on pDCs, PBMCs are not 
permissive for HCV infection131. 
The results in this work and from other groups show that pDC activation is clearly more 
efficient when cell-cell contacts with HCV SGR cells are possible. On one side this might 
be due to a direct transfer of viral RNA into pDCs, but it is tempting to speculate that this 
interaction might increase pDC activation due to additional signals comparable to co-
stimulatory molecules in immunological synapses132. A similar hypothesis was also 
formulated by other authors133. The above discussed interaction between CD81 and CD9 
could be part of an interaction within a potential synapse. Also the observed up-regulation 
of CD38 and CD44 in HCV SGR cells (Fig. 4-35 B, C) could play a role. Especially, CD38 
might be involved as it interacts with CD31134 and CD31 is highly expressed on 
monocytes135. However, blocking CD31 or CD38 and siRNA mediated knockdown of 
CD38 in HCV SGR cells had no effect on monocyte uptake in the co-culture of HCV SGR 
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cells with PBMCs or with purified monocytes (data not shown). Nevertheless, if in fact a 
synapse with multiple interactions between HCV infected cells and immune cells is formed, 
eliminating one molecule of interaction might not be sufficient. Thus, formation of synapses 
should be studied by other methods like microscopy. 
 
5.2 NK cell activation in response to HCV SGR cells 
Next to IFNα secretion by pDCs, it was analyzed by a Luminex assay if also other 
cytokines were produced in the co-culture of HCV SGR cells and PBMCs (Fig. 4-10). 
Secretion of specific cytokines or chemokines could provide evidence that other innate 
immune cells contribute to the anti-viral response. Indeed, IFNγ secretion was detected in 
the Luminex assay, which indicated an activation of NK cells (a role of T cells was 
excluded as the short overnight co-culture is not sufficient to allow a response of adaptive 
immune cells from healthy donors). This was further confirmed by ELISA (Fig. 4-11 A, B). 
But interestingly, purified NK cells did not respond with IFNγ secretion (Fig. 4-11 C), 
suggesting that NK cells need interaction with other immune cells. Monocyte depletion 
from PBMCs resulted in nearly complete loss of IFNγ (Fig. 4-24). This demonstrated that 
IFNγ secretion by NK cells depends on monocytes, which is in line with previous 
findings82. In that study it was shown that monocytes react with inflammasome activation 
to HCV SGR cells, which leads to IL-18 secretion which in turn drives NK cell activation 
and IFNγ secretion. Here, up-regulation of IL-18 was also detected in the Luminex assay 
(Fig. 4-10). Moreover, it has been shown that also pDC derived IFNα has an influence on 
NK cell activation in an HCV context102. In the latter study it was observed that purified NK 
cells failed to secrete IFNγ and by depletion and cytokine stimulation experiments that 
pDCs and monocytes drive NK cell activation. Also Kupffer cells, the liver resident 
macrophages, have been shown to be able to activate NK cells in HCV infected 
livers136,137. These studies demonstrated that Kupffer cells respond to TLR ligands and 
drive NK cell activation by cytokine secretion (e.g. IL-18). Thereby, the results indicate the 
relevance of the in vitro experiments in this work and other studies. 
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5.3 Monocyte activation in response to HCV SGR cells  
5.3.1 Chemokine secretion indicates monocyte activation 
As discussed before, NK cell activation in the co-culture with HCV SGR cells depends on 
monocytes. Accordingly, monocytes first have to be activated before they can drive NK cell 
activation. In the Luminex assay a set of cytokines and chemokines were up-regulated that 
hinted at a role of monocytes (TNFα, IL-6, IL-8, MCP-1, IP-10, MIP-1α and MIP-1β, Fig. 4-
10) as all of them can be secreted by monocytes138–141. Expression of these cytokines and 
chemokines was also confirmed by qPCR (Fig. 4-12). Interestingly, others have observed 
a similar expression profile of cytokines and chemokines in co-cultures of HCV SGR cells 
with PBMCs82. In that study also expression of TNFα, MCP-1, IP-10 and MIP-1β was 
detected. 
Of particular interest was the secretion of IP-10, as this was described to be expressed in 
patients with HCV infection. Hepatocytes are a major source of IP-10 during HCV infection 
in vivo and in vitro142,143. The production of IP-10 in the liver leads to the recruitment of T 
cells, NK cells, and monocytes144. It has also been shown that IP-10 is induced primarily 
through an IFN-independent pathway following PRR signaling in the HCV-infected 
hepatocyte in vitro and that type I and type III IFNs produced by non-parenchymal cells 
amplify IP-10 induction in primary human hepatocytes145.  
Next to IP-10, also the chemokine IL-8 was secreted (Fig. 4-10). To investigate if 
monocytes in fact secrete these chemokines, intracellular staining for IL-8 was performed 
after co-culture with HCV SGR cells (IL-8 was chosen as functioning antibodies for 
intracellular staining are available). Surprisingly, IL-8 was not secreted by monocytes but 
by HCV SGR cells (Fig. 4-13). Although previous reports have shown that viral proteins 
can induce IL-8 secretion in infected cells146–148, IL-8 was not secreted by HCV SGR cells 
per se. Thus, PBMC activation seems to induce signaling in HCV SGR cells which leads to 
the secretion of IL-8. Thereby, IL-8 as a chemokine attracts further immune cells to the 
infected cell149. 
Despite no secretion of IL-8 by monocytes, intracellular IL-8 staining by chance revealed 
that monocytes take up material from HCV SGR cells (Fig. 4-13), finally indicating that 
monocytes indeed are involved in the anti-viral response. 
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5.3.2 Uptake of HCV SGR cells by monocytes 
In co-cultures of CFSE-stained HCV SGR cells with PBMCs it was observed that nearly all 
monocytes became CFSE positive (Fig. 4-14). ImageStream analysis revealed that 
monocytes phagocytose small vesicles originating from HCV SGR cells (Fig. 4-15). These 
vesicles suggested that HCV SGR cells are driven into apoptosis by activated PBMCs. In 
fact, LDH release assays showed that HCV SGR cells are killed by PBMCs (Fig. 4-25 A). 
Moreover, caspase inhibition experiments (Fig. 4-26) and cleaved PARP assays (Fig. 4-25 
B) demonstrated that PBMCs trigger apoptosis in HCV SGR cells. Thus, monocytes take 
up apoptotic vesicles from HCV SGR cells, which again raised the question if monocytes 
play an active role in the anti-viral response or if they only passively take up apoptotic 
vesicles. To answer this, purified monocytes were co-cultured with CFSE-stained HCV 
SGR cells. Also in this setup monocytes were taking up HCV SGR cells, although 
compared to monocytes within PBMCs to a lower extent (Fig. 4-19). However, time course 
experiments revealed that monocyte uptake occurs before interferons were secreted (Fig. 
4-23). In addition, depletion of monocytes from PBMCs reduced killing activity of the 
remaining immune cells (Fig. 4-27 B). Taken together these results indicated that 
monocytes actively contribute to the response against HCV. Hence, this study confirms 
findings of an active role of monocytes, in which monocytes were shown to respond by 
inflammasome activation and IL-18 secretion in response to HCV infected cells82. 
 
5.4 Interaction of innate immune cells in the response against HCV 
Previous results showed that pDCs, NK cells and monocytes are activated in co-culture 
with HCV SGR cells. Purified pDCs and pDCs within PBMCs secreted similar amounts of 
IFNα (Fig. 4-1), arguing for a direct recognition of HCV SGR cells by pDCs independent of 
other innate immune cells (see 5.1). Still, pDC activation alone was not sufficient to induce 
killing of HCV SGR cells (Fig. 4-27 A). Besides, purified NK cells and monocytes had 
impaired functions compared to their phenotype within PBMCs. 
 
5.4.1  NK cell activation depends on monocytes and pDCs 
Purified NK cells did not secrete IFNγ (Fig. 4-11 C) and failed to kill HCV SGR cells (Fig. 
4-27 A). IFNγ production by NK cells was shown to be dependent on monocytes (Fig. 4-
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24). As discussed above in detail (see. 5.2) this was in line with another report82). A further 
study suggested that pDCs are also important for IFNγ secretion by NK cells102 (see 5.2). 
Moreover, NK cells were found to express the activation markers CD69 and CD25 and the 
apoptosis inducing ligand TRAIL on the surface in co-culture of HCV SGR cells with 
PBMCs (Fig. 4-28). Subsequently, it was shown that TRAIL induced apoptosis in HCV 
SGR cells, as blocking TRAIL by a specific antibody significantly reduced killing and 
uptake of HCV SGR cells (Fig. 4-29). Earlier reports have shown that expression of TRAIL 
by NK cells in the context of HCV infection depends on IFNα103,104,150. Hence, IFNα 
secretion by pDCs in this co-culture system is driving TRAIL expression on NK cells and 
thereby apoptosis of HCV SGR cells. 
 
5.4.2  Monocyte activation is enhanced by pDCs and NK cells 
Purified monocytes were impaired in uptake of HCV SGR cells compared to monocytes 
within PBMCs (Fig. 4-19), but still showed a significant response, which confirmed other 
studies that showed a direct recognition by monocytes of HCV infected cells82. 
Interestingly, monocyte uptake was not reduced when NK cells or pDCs were depleted 
from PBMC, but dropped significantly when both, NK cells and pDCs were depleted (Fig. 
4-21). This indicated that pDCs and NK cells have redundant roles. Also addition of IFNα 
or IFNγ boosted the uptake of HCV SGR cells by purified monocytes (Fig. 4-22 A, B). Yet 
pre-incubation of monocytes or HCV SGR cells alone with interferon was not sufficient to 
boost the uptake, both cells had to be exposed to interferon during the co-culture (Fig. 4-
22 C-F). This suggested that interferons act on monocytes as well as on HCV SGR cells. 
Nevertheless, this indicated that monocyte action is enhanced by pDCs and NK cells. In 
addition, an activation of monocytes by accessory cells is supported by the observation 
that monocytes within PBMCs showed strong up-regulation of activation markers CD80 
and CD86 (Fig. 4-18), while purified monocytes displayed only slight up-regulation (Fig. 4-
20). 
A similar effect of pDCs and NK cells on monocytes has not been observed before in an 
HCV context. In a study dealing with pneumonia caused by influenza virus it was shown 
that type I interferons cause up-regulation of TRAIL on alveolar macrophages151. However, 
TRAIL was not detected on monocytes in this study, neither in the co-culture of HCV SGR 
cells with complete PBMCs nor with purified monocytes supplemented with IFNα (data not 
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shown). Also blocking TNF had no effect on the uptake by purified monocytes (data not 
shown). Another study in a murine model demonstrated that alveolar macrophages 
secrete type I interferons in response to the respiratory syncytial virus152. This triggered 
chemokine secretion by monocytes which in turn recruited inflammatory monocytes to the 
lungs. These inflammatory monocytes were then able to control viral infection. But similar 
to this study, the mechanism underlying elimination of infected cells could not be 
explained. Still, the data in this work provide evidence that pDCs and NK cells act on 
monocytes, which again highlights the importance of the interplay between innate immune 
cells. 
 
5.4.3  Combined activation of innate immune cells leads to killing of HCV SGR cells 
Complete PBMCs were able to kill HCV SGR cells (Fig. 4-25). However, purified pDCs, 
NK cells or monocytes were not sufficient to induce killing (Fig. 4-27 A). Nevertheless, 
each of these subsets of immune cells contributes to killing, as depletion of each of them 
resulted in lower killing efficiency of HCV SGR cells (Fig. 4-27 B). Again, this confirms the 
necessity for interactions of innate immune cells to initiate an immune response which is 
leading to killing and clearance of HCV SGR cells. Mechanistically, TRAIL expression on 
NK cells was found to induce apoptosis in HCV SGR cells (Fig. 4-28, Fig. 4-29). As 
discussed before, IFNγ secretion by NK cells depends on monocytes (Fig. 4-24) and 
TRAIL expression on IFNα103,104. The interactions between innate immune cells and how 
this leads to killing and clearance of HCV SGR cells are summarized in Fig. 5-1. 
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Fig. 5-1 Interaction of innate immune cells in response to HCV SGR cells 
Schematic overview of the interactions of innate immune cells leading to anti-viral responses. pDC is 
depicted in cyan, monocyte in green, NK cell in red, viral RNA in purple and TLR7 inside the pDC in black. 
pDCs are activated by viral RNA in cell-cell contact dependent manner and secrete IFNα in response. IFNα 
inhibits viral replication and activates monocytes and NK cells, which leads to TRAIL expression on NK cells. 
Monocytes are also activated by HCV SGR cells. By secretion of IL-18 monocytes trigger IFNγ production in 
NK cells. IFNγ in turn also inhibits viral replication. TRAIL on NK cells induces apoptosis in HCV SGR cells, 
but not in uninfected cells. Moreover, IFNα from pDCs and IFNγ from NK cells act on monocytes and 
enhance a yet unknown mechanism by which monocytes kill HCV SGR cells. Finally, apoptotic bodies from 
HCV SGR cells are cleared by monocytes. 
 
However, other mechanisms of killing are exerted by PBMCs within the co-culture of HCV 
SGR cells with PBMCs. This is supported by the results of NK depletion experiments. 
Upon NK depletion neither killing nor uptake of HCV SGR cells was completely lost (Fig. 4-
27 B, Fig. 4-21). Moreover, purified monocytes in co-culture with HCV SGR cells in 
presence of interferons exerted some killing activity and the uptake was boosted (Fig. 4-
22). Thus, activated monocytes are able to kill HCV SGR cells, since IFNα alone did not 
induce killing of HCV SGR cells (no kill by purified pDCs despite IFNα secretion, Fig. 4-27 
A, Fig. 4-1 C). Although intensively investigated, the mechanism behind killing by 
monocytes could not be figured out. Monocytes are known to engage several mechanisms 
to kill target cells. For example, expression of Granzyme B153, TNFα154 or TRAIL155,156 can 
lead to killing of target cells. Granzyme B expression was analyzed by qPCR in the co-
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culture of purified monocytes and HCV SGR cells, but no up-regulation was detected (data 
not shown). Besides, neither TNF nor TRAIL blocking inhibited uptake by purified 
monocytes in presence of IFNα (data not shown). Thus, it remains unclear how monocytes 
kill HCV SGR cells. In other studies with HCV infected cells killing by monocytes thus far 
has not been described. As discussed before (see 5.4.2), studies with influenza virus have 
shown that TRAIL expression on monocytes in response to IFNα can kill infected cells151, 
but TRAIL had no effect in this study (see above). Moreover, Goritzka et al. observed 
killing of respiratory syncytial virus infected cells by inflammatory monocytes in the murine 
system152, but also struggled to identify the underlying mechanism. Nevertheless, it was 
proven that also the mechanism that enables monocytes to take up HCV SGR cells relies 
on interaction with other immune cells (Fig. 4-21, Fig. 4-22). 
 
5.5 Specific killing of HCV infected cells 
5.5.1 TRAIL in HCV infection 
Similar to the observation in this study that TRAIL expressed on NK cells can induce 
apoptosis of HCV infected cells, in vitro studies with recombinant TRAIL showed that HCV 
infected cells can be killed by TRAIL157,158. However, it was also described that TRAIL 
unspecifically targets liver cells from HCV patients due to up-regulation of the pro apoptotic 
TRAIL receptors DR4 and DR5159. Conflicting with this was another study in which no up-
regulation of DR4 and DR5 was found on hepatocytes in vivo during chronic hepatitis and 
with a study where no unspecific killing by TRAIL was induced in vivo160,161. The different 
results regarding DR4 and DR5 expression in patient samples might be explained by 
varying conditions in patients. For example, the infection status (acute or chronic) could 
have an influence on expression of TRAIL receptors. In addition, the immune response by 
each patient could inhibit or trigger expression of DR4 and DR5 via cytokine induced 
signaling. Also studies working with hepatoma cell lines replicating HCV had differential 
results regarding up-regulation of DR4 and DR5157,158,162. As cells lines are derived from a 
specific clone even the same cell lines often show different phenotypes, which of course is 
a major drawback of cell lines. On HCV SGR cells and Huh-7 control cells used in this 
study no differential expression in pro-apoptotic TRAIL receptors DR4 and DR5 and in the 
anti-apoptotic DcR2 receptor was detected (Fig. 4-30). Also flow cytometry measurements 
revealed no differences (data not shown). 
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5.5.2 HCV SGR cells are sensitive towards TRAIL 
Since expression of TRAIL receptors between HCV SGR cells and Huh-7 cell was 
comparable, it was questionable if HCV activated PBMCs also target uninfected control 
cells. As discussed before, unspecific killing of uninfected cells in vivo would lead to 
harmful liver damage. To address this question, triple co-cultures of Huh-7, Huh-7 Con1 
and PBMCs were set up. Strikingly, PBMCs did only kill HCV SGR cells, but not Huh-7 
cells (Fig. 4-32, Fig. 4-33). Thus, TRAIL mediated killing in this experimental setup is 
specific for infected cells. However, this raised the question why killing is specific, as 
TRAIL receptors are not differentially expressed. It was found that recombinant TRAIL 
induced apoptosis only in HCV SGR cells (Fig. 4-36 A, C, D). This effect was specific for 
TRAIL, as TNF had no significant effect (Fig. 4-36 B). 
In a former study it was shown, that sensitization towards TRAIL is a result of 
mitochondrial damage in HCV infected cells158. The authors showed that mitochondrial 
damage is caused by non-structural proteins of HCV and that caspase-9 signaling occurs. 
Capase-9 is activated by mitochondrial damage and mediates the intrinsic apoptosis 
pathway163. It was shown that an external apoptotic signal is not sufficient to drive 
apoptosis in hepatocytes, but that a second internal apoptotic signal like mitochondrial 
damage is required164. Thus, together with the extrinsic induction of apoptosis via TRAIL, 
the infected cell undergoes apoptosis. Thereby, it can be explained why in this study in the 
model of acute infection only HCV SGR cells are targeted. Nevertheless, in a chronic HCV 
infection in vivo it is conceivable that also uninfected cells become sensitive to external 
apoptosis induction due to the constant exposition to various cytokines, which could result 
in unspecific liver damage. Regarding the mitochondrial damage in HCV infected cells 
observed by Lan et al. 158, it is tempting to speculate that mitochondrial damage arises 
from MAVS cleavage. MAVS is a mitochondrial membrane protein involved in RLR 
signaling165 and can be cleaved by the viral NS3/4A protease48. This hypothesis could be 
tested by analyzing if cells expressing a cleavage-resistant MAVS mutant are also 
sensitive to TRAIL induced apoptosis. 
In addition to specific killing due to TRAIL sensitization, it is speculated that specificity for 
infected cells might also arise from direct interactions of innate immune cells. Potentially, 
NK cells might only be activated at sites where pDCs and monocytes are activated by 
direct contact with HCV infected cells. Thus, the interaction of innate immune cells might 
increase specificity by coupling recognition of infected cells and effector mechanisms. This 
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hypothesis to a certain degree is supported by the observation that NK cells displayed 
stronger adherence to HCV SGR cells compared to Huh-7 control cells (Fig. 4-34). This 
speculated process might function similar to the complement system, the humoral part of 
the innate immune system (reviewed in Merle et al.166). In brief, pathogens are marked by 
the complement system by various mechanisms, which in turn leads to specific targeting of 
the marked pathogens e.g. by opsonization. In the context of this study, pDCs and 
monocytes sense HCV infected cells by direct contact and respond by cytokine secretion. 
In addition, it was observed that immune cells drive chemokine secretion by HCV SGR 
cells (Fig. 4-13). This high local concentration of cytokines might act as a marker for an 
ongoing infection and could lead to site-specific activation of NK cells. Thereby, NK cells 
could specifically target infected cells. It is currently investigated if this hypothesized 
interaction between innate immune cells takes place in the liver of HCV infected patients. 
Therefore, monocytes and NK cells are stained in liver slides and analyzed for co-
localization. 
 
5.5.3 PBMCs are specifically activated by HCV, but not by DV and HAV SGR cells 
Next to specificity in killing HCV SGR cells without targeting uninfected cells, activation of 
PBMCs was specific for HCV. DV and HAV SGR cells were not taken up by monocytes 
(Fig. 4-17), suggesting that PBMCs are not activated in this setting. Indeed, both types of 
SGR cells did not induce IFNα secretion and supernatants of the co-culture with PBMCs 
did not inhibit viral replication in the highly sensitive luciferase assay (data not shown). It 
was shown that IFNα secretion correlated with the amount of HCV RNA secreted from 
different HCV SGR cells (Fig. 4-3). DV and HAV SGR cells secreted lower amounts of viral 
RNA compared to HCV (data not shown). Hence, PBMCs are not activated by SGR cells 
replicating DV or HAV RNA. In addition, due to GU-rich sequences HCV RNA can be 
recognized by TLR7 and TLR8120,128, which could also explain why innate immune cells 
react to HCV, but not to DV or HAV SGR cells. Furthermore, it has been shown that 
immature viral particles of DV stimulated pDCs167. In another study it was demonstrated 
that pDCs sense enveloped virions of HAV168. As SGR cells lack structural proteins no 
particles can be produced, which might explain the lack in PBMC activation with DV and 
HAV SGR cells. Interestingly, both studies observed that pDC activation required direct 
contact with infected cells, which as discussed before is in line with findings for HCV. 
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To test if DV and HAV RNA activate PBMCs, RNA from these viruses could be transfected 
into PBMCs. If indeed a sequence specific recognition leads to a response against HCV 
RNA, DV and HAV RNA should not activate PBMCs. However, it has been shown that 
modifications of RNAs can also inhibit stimulation of immune cells169. Thus, transfection 
experiments of viral RNA should be performed with in vitro transcripts lacking 
modifications and with purified viral RNA from host cells that carry different modifications. 
If also DV and HAV RNA would stimulate immune cells, this would indicate that indeed the 
reduced secretion of viral RNA compared to HCV accounts for the lack of PBMC 
stimulation. 
Moreover, it could be analyzed if DV or HAV SGR cells are killed by PBMCs when 
recombinant IFNα and/or IFNγ is added to the co-culture. Alternatively, triple co-cultures of 
PBMCs with HCV and DV or HAV SGR cells could be set up. That would give insight if DV 
and HAV SGR cells are killed by activated PBMCs and if DV and HAV similar to HCV 
sensitize host cells for TRAIL mediated apoptosis. 
 
5.6  Innate immunity and the outcome of HCV infection  
With the experimental setup in this study, the co-culture of HCV SGR cells with PBMCs 
from healthy donors, an acute infection is mimicked. Indeed, the results clearly show that 
innate immune cells elicit an anti-viral response that leads to killing and clearance of 
infected cells. Hence, it is remarkable why 70-80% of HCV infections lead to chronic 
infection while only 20-30% spontaneously clear the virus170. Other reports provided 
evidence that the adaptive immune response and cytotoxic T cells in particular determine 
the outcome of HCV infection (reviewed in171). Due the short time frame of the 
experiments performed in this study adaptive immunity had no influence. Nevertheless, it 
might be speculated that the interaction and mutual activation of innate immune cells might 
also influence the onset and magnitude of the adaptive immune response.  
The results of this study demonstrated that the innate immune response rapidly leads to 
apoptosis and clearance of infected cells. Via uptake of apoptotic bodies of HCV infected 
cells, antigen presenting cells might be able to display HCV specific antigens to cells of the 
adaptive immune system. Moreover, activation of antigen presenting cells in the context of 
the anti-viral response might also lead to up-regulation of co-stimulatory molecules, which 
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are essential in activating T cells. Yet, an efficient innate immune response relies on 
interaction of different immune cells and it is questionable if these interactions in vivo occur 
as fast as in this in vitro model. Thus, it could be speculated that a race between the 
immune response and the establishment of infection takes place in which HCV inhibits 
several immune responses. In case of a fast response innate immune cells could rapidly 
activate adaptive immune cells that finally clear the virus, before HCV exerts its immune-
modulatory functions. However, it might also be speculated that a strong innate immune 
response could limit adaptive immunity. By killing and clearance of HCV infected cells, the 
number of infected cells is kept at a low percentage, which in turn could help the virus to 
establish a chronic infection below the radar of adaptive immunity.  
 
5.7  Conclusion & Outlook 
In summary, in this work it is shown how interaction of different innate immune cells in 
response to HCV infected cells shapes the immune response (summarized in Fig 5-1). 
While pDCs and monocytes are directly activated by recognition of viral RNA, the 
interaction facilitates additional mutual activation of innate immune cells. Consequently, an 
efficient immune response is exerted that ultimately leads to killing of HCV infected cells 
by TRAIL expression on NK cells and other thus far unidentified mechanisms. In addition, 
it was demonstrated that innate immune cells activated by HCV in this acute infection 
model do not target uninfected cells. Nevertheless, some important aspects were not 
addressed in this study or could not be answered yet. Thus, additional experiments could 
be performed to further understand the innate immune response against HCV. 
Whether similar interactions between innate immune cells also occur in the infected liver is 
subject of current analysis. Co-localization of NK cells and monocytes is investigated in 
liver tissue slides from HCV patients. However, a direct co-localization is not necessarily 
essential, as the results of this and other studies indicated that mutual activation also relies 
on cytokine secretion.  
An additional interesting topic that arose from the results of this study is to investigate the 
mechanism underlying transfer of viral RNA from infected cells into pDCs. It was 
demonstrated that pDC activation was dependent on direct cell-cell contact with HCV SGR 
cells (Fig. 4-8). As discussed before (see 5.1.2) it is speculated that a synapse between 
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infected cells and pDCs is formed that allows transfer of HCV RNA into pDCs. To 
experimentally test this assumption, microscopy studies could be performed to analyze if 
such a synapse is formed and to identify molecular players involved in this contact by 
fluorescently tagged proteins or antibodies (which however could also disturb potential 
interactions). It would also be interesting to analyze if pDCs display stronger binding to 
HCV SGR cells compared to Huh-7 control cells (for example by atomic force microscopy). 
Although no major differences were found in the surface proteome of these cells (Fig. 4-
35), it is still possible that pDCs somehow recognize infected cells from the outside. If 
binding to HCV SGR cells and control cells would be of similar strength, it would indicate 
that infected cells are not recognized from the outside.  
Next to further analysis regarding pDCs, it remains unclear how purified monocytes in co-
culture with HCV SGR cells in presence of IFNα or IFNγ mediate killing of infected cells 
(Fig. 4-22). Thus far, a role of Granzyme B, TRAIL and TNFα was excluded. Another 
option could be the analysis of the gene expression in purified monocytes upon stimulation 
with interferons by microarray. Thereby, potential new candidates might be found that 
could explain how monocytes kill HCV SGR cells. An effect of these candidates then could 
be analyzed by knockdown or blocking experiments. 
At last, it should be experimentally investigated if the interaction of innate immune cells is 
beneficial for the activation of adaptive immune cells. This could be analyzed by setting up 
the co-culture of HCV SGR cells and PBMCs. Subsequently, different populations 
(monocytes, pDCs and classical DCs) could be purified. Purified cells could then be co-
cultured with T cells to analyze if T cells become activated by HCV specific antigens 
presented by innate immune cells (that were in contact with HCV SGR cells). Alternatively, 
after co-culture with HCV SGR cells purified innate immune cells could also be spiked with 
tetanus antigen (which most people are vaccinated against). Then it could be analyzed if T 
cells show a stronger response in co-culture with innate immune cells that were previously 
co-cultured with HCV SGR cells compared to Huh-7 control cells. That at least would 
indicate that exposure to HCV SGR cells increases the co-stimulatory potential of innate 
immune cells. If these experiments are feasible, the initial co-culture with HCV SGR cells 
could be performed with purified innate immune cells or with PBMCs depleted from 
specific subsets. If T cell activation in that case would be impaired it would indicate that the 
interaction of innate immune cells is also required for an efficient activation of adaptive 
immunity. 
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The activation of adaptive immunity by innate immune cells could also be analyzed in a 
murine model. In this work it was shown that murine BMDM respond to HCV SGR cells 
(Fig. 4-5). In addition, T cells from OT-I mice that express a T cell receptor that recognizes 
ovalbumin presented by MCH class I could be used172. Then it could be tested if BMDM 
activated by HCV SGR cells and pulsed with ovalbumin induce a stronger T cell response 
compared to BMDM that were cultured with hepatoma cells without HCV replication. 
However, a drawback of the murine model would be the missing interactions between 
innate immune cells. It is not known if other cell types in the murine system respond to 
HCV SGR cells and it would require additional work to investigate this. 
To conclude, this work demonstrates that interacting innate immune cells respond to HCV 
and provide a rapid and efficient response, but further details of the innate immune 
response need to be investigated. And finally it needs to be analyzed how the innate 
immune response influences adaptive immunity to better understand why some patients 
clear the virus and the majority develops a chronic infection. 
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